Antibody Drug Conjugates

Through non-immunogenic polymer modification and site-specific conjugation technology, pegylated antibody drug conjugates were prepared, solving the toxicity and manufacturing complexity of traditional ADCs, and achieving high-efficiency and low-toxicity anti-tumor effects .

CN114502200BActive Publication Date: 2024-11-29SHENZHEN ENDURING BIOTECH LTD
View PDF 40 Cites 0 Cited by

Patent Information

Application Number
CN202180005506.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-04-15
Publication Date
2024-11-29
Estimated Expiration
2041-04-15

AI Technical Summary

Technical Problem

Existing antibody drug conjugates (ADCs) have toxicity problems in the treatment of cancer, especially traditional ADCs carrying Fc show inherent toxicity and off-target toxicity in clinical applications, and the manufacturing process is complex and difficult to penetrate into solid tumors. .

Method used

Polyethylene glycolized monospecific or bispecific antibody drug conjugates are prepared by site-specific conjugation through non-immunogenic polymer modification, and polyethylene glycol is used to perform site-specificity with antibody or antibody fragments. Conjugation to form a homogeneous conjugate with high potency and low toxicity.

Benefits of technology

It has achieved the reduction of toxicity, expanded the treatment window, enhanced anti-tumor effects, and deeply penetrated into solid tumors through small-sized single-chain antibody molecules, improving the cancer treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003561980710000032
    Figure BDA0003561980710000032
  • Figure BDA0003561980710000041
    Figure BDA0003561980710000041
  • Figure BDA0003561980710000042
    Figure BDA0003561980710000042
Patent Text Reader

Abstract

The present invention provides an antibody drug conjugate (ADC), in particular a pegylated monospecific or multispecific antibody drug conjugate (BsADC) prepared by site-specific conjugation to provide a homogeneous conjugate with high efficacy and low toxicity. It also relates to a method for preparing ADC, a compound containing ADC and its use in treating diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of the filing date of PCT application number PCT / CN2020 / 084880, filed on April 15, 2020, the entire contents of which are incorporated by reference for all purposes. Technical Field

[0002] The present invention relates to antibody drug conjugates (ADCs), and in particular to multispecific antibody drug conjugates prepared by site-specific conjugation to provide homogeneous conjugates with high efficacy and low toxicity. In particular, the present invention relates to long-acting PEGylated monospecific or bispecific single-chain antibody drug conjugates prepared by site-specific conjugation of PEGylated drugs to monospecific or bispecific antibodies. Background of the Invention

[0004] Cancer treatment has been progressing slowly, from surgery (late 19th century) to radiotherapy (early 20th century), from chemotherapy and hormone therapy (mid-20th century) to targeted drugs (1990s), and from the combination of targeted drugs with chemotherapy and hormones (early 21st century) to the recent antibody drug conjugates (ADCs), etc. The concept of using ADCs to treat cancer can be traced back to more than 50 years ago (Decarvalho, S. et al., Nature, 1964, 202, 255-258): using antibodies as carriers to deliver extremely potent substances directly to tumor cells. Early ADCs used non-humanized antibodies that were antigenic in themselves, β-emitting radionuclide payloads that were difficult to obtain and use, and unstable linkers that released cytotoxic payloads prematurely. Today's ADC technology uses humanized antibodies, highly cytotoxic organic payloads, and relatively stable linkers that are designed to maintain the integrity of the cell killer until it reaches the target and the entire ADC molecule is internalized into the cell.

[0005] In the United States, 10 ADCs have been approved by the FDA, all of which are used for cancer treatment, and more than 100 ADC candidate drugs are currently active in clinical trials (Beacon Targeted Therapies Research Report | Hansonwade). All ten approved ADCs show serious side effects during treatment. In fact, 8 of the 10 approved ADCs need to carry black box warning labels, which limits their application in various cancer indications. The biggest challenge of IgG-based ADCs today is the requirement to be administered very close to the maximum tolerated dose (MTD) to show therapeutic benefits, which leads to a very narrow therapeutic window (Beck, A. et al., Nat. Rev. Drug Discov., 2017, 16, 315-337; Vankemmelbeke, M. et al., Ther. Deliv., 2016, 7, 141-144; TolcHer AW et al., Ann. Oncol., 2016, 27, 2168-2172). In addition, the toxicity characteristics found on these ADCs are comparable to those of standard-of-care chemotherapy drugs, with dose-limiting toxicity associated with cytotoxic warheads (Coats, S. et al. Clin. Cancer Res., 2019, 25, 5441-5448). Of the approximately 80 traditional ADCs terminated in clinical trials, most were terminated due to poor therapeutic windows or indices compared to existing therapies. There is ample evidence that the hydrophobicity of the conjugated site and the linker / drug has a significant effect on the stability, efficacy, and therapeutic index of the ADC, and that site-specific conjugation of cytotoxic molecules to antibodies with hydrophilic linkers can improve the therapeutic index (Junutula, JR et al., Nat. Biotechnol., 2008, 26, 925-932; Lyon, RP et al., Nat. Biotechnol., 2015, 33, 733-735). However, many ADCs currently in clinical development or on the market require cleavage of two or more interchain disulfide bonds of full-length antibodies to obtain high DARs. Unfortunately, this approach may lead to protein instability. This is especially true for BsADCs carrying Fc, because bispecific antibodies are non-natural antibodies, and it is more difficult to make BsADCs carrying Fc with high DAR. Many other ADCs in development or approved are prepared by random conjugation to cysteine ​​residues or lysine residues of antibodies and are heterogeneous in nature, which brings difficulties to analysis and precise administration in clinical settings. Moreover, ADC molecules constructed from full-length antibodies are considered too large, making it difficult to penetrate deeply into dense solid tumors to treat mid- to late-stage cancers.In addition, all traditional ADCs carrying Fc have intrinsic toxicity due to the binding of their Fc to FcγRIIa on megakaryocytes (MKs) and subsequent internalization, which then kills megakaryocytes, ultimately leading to the cessation of platelet production and thrombocytopenia (Uppal, H. et al., Clin Cancer Res; 21(1) January 1, 2015), and many off-target toxicities observed for antibody drug conjugates are also driven by mannose receptor uptake directly associated with the Fc component of ADCs (Gorovits, B. et al., 2013, Cancer Immunol Immunot Her 62, 217-223).

[0006] Therefore, new ADC technologies with enhanced efficacy and improved toxicity profiles are urgently needed. SUMMARY OF THE INVENTION

[0008] The present invention addresses the above unmet needs by providing non-immunogenic polymer-modified antibody drug conjugates prepared by site-specific conjugation of polymer-modified (e.g., pegylated) drug conjugates to monospecific or multispecific antibody fragments, or to monospecific or multispecific single-chain antibodies, through engineered sites (e.g., cysteine) for site-specific conjugation. Antibody fragments or single-chain antibodies can be monovalent or multivalent to antigens.

[0009] In one aspect, the present invention provides The polymer antibody drug conjugate molecule. P can be a non-immunogenic polymer. T can be a multifunctional (e.g., trifunctional) small molecule linker portion and has at least one functional group capable of site-specific conjugation with a monospecific or multispecific antibody or protein. A can be any monospecific or multispecific antibody or protein. D can be any cytotoxic small molecule or peptide (n≥1), and each D can be the same or different.

[0010] In particular, one aspect of the present invention provides a conjugate of formula Ib:

[0011]

[0012] in:

[0013] P may be a non-immunogenic polymer;

[0014] M can be H or selected from C 1-50 Alkyl and aryl end-capping groups, wherein one or more carbons of the alkyl group are optionally substituted with heteroatoms;

[0015] y may be an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

[0016] T can be a multifunctional linker having two or more functional groups, including but not limited to trifunctional or tetrafunctional or any other cyclic or non-cyclic multifunctional moiety (e.g., lysine), wherein T and (L 1 )a and the connection between T and (L 2 ) b The connections between can be the same or different;

[0017] L 1 and L 2 Each of can independently be a bifunctional linker;

[0018] a and b can each be an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

[0019] B may be a branched linker, wherein each branch may comprise an extended spacer, a trigger unit, a self-immolating spacer or any combination thereof, wherein the trigger unit may be an amino acid sequence or a trigger portion cleaved by an enzyme, a pH-sensitive linker that can release drug D or its derivative under acidic pH conditions, or a disulfide bond linker that can release drug D or its derivative by chemical or enzymatic cleavage, or a cleavable bond that can release drug D by a specific cleavage mechanism;

[0020] A can be any monospecific or multispecific antibody or antigen-binding protein, including an antibody fragment, a single-chain antibody, a nanobody or any antigen-binding fragment, which can be monovalent or multivalent against an antigen.

[0021] D can be any cytotoxic small molecule or peptide or derivative thereof and can be released from B by enzymatic cleavage and / or self-immolating mechanism or pH-induced hydrolysis with or without self-immolating mechanism; each D can be the same or different;

[0022] n may be an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.

[0023] Another aspect of the present invention provides a conjugate of formula Ic:

[0024]

[0025] wherein each variable is as defined in Formula Ib.

[0026] In some embodiments, each branch of B comprises a trigger moiety, such as an amino acid sequence or a disulfide moiety or a β-glucoside or β-galactosamine, which is linked to the drug D via a self-immolative spacer or directly linked to the drug D, which is cleaved by, for example, cathepsin B, plasmin, matrix metalloproteinase (MMP), glutathione, thioredoxin, thioreductase (Arunachalam, B. et al., 2000, PNAS, 97 (2) 745-750). Examples of self-immolative spacers include, but are not limited to, the following:

[0027]

[0028] Where R 1 , R 2 , R 3 , R 4 Can be H or C 1-10 In such embodiments, D can be any small molecule or peptide or derivative thereof containing a reactive O or N or S functional group.

[0029] In some embodiments, each branch of B can be a pH-sensitive linker, which can release drug D or its derivative under acidic pH conditions at the tumor site and / or inside tumor cells. Examples of acidic liable linkers include, but are not limited to, the following forms:

[0030] -CR 1 =N-NR 1 -、-CR 1 =NO-, -CR 1 =N-NR 2 -CO-, -N=N-CO-, -OCOO-, -NR 1 -COO-.

[0031] In some embodiments, each branch of B can be a disulfide bond linker, which can release drug D or its derivative at the tumor site and / or inside the tumor cell by chemical or enzymatic cleavage, such as glutathione, thioredoxin family member (WCGH / PCK) or sulfhydryl reductase enzymatic cleavage.

[0032] In some embodiments, A is a monospecific antibody that is monovalent or divalent against the antigen, such as a monospecific single chain antibody that is monovalent or divalent against the antigen.

[0033] In some embodiments, A is a multispecific antibody, such as a bispecific single chain antibody.

[0034] In some embodiments, the two binding domains of the bispecific antibody bind to two identical tumor-associated antigen (TAA) molecules at two different epitopes, or bind to two different tumor-associated antigen molecules.

[0035] In another embodiment, A is a single chain anti-Her2 x anti-Her2 antibody (SCAHer2xSCAHer2), which binds to Her2 expressed on cancer cells. The two binding domains of the SCAHer2xSCAHer2 antibody can bind to the same epitope on two Her2 molecules, or to two different epitopes on two Her2 molecules. In some embodiments, the antibody has an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2.

[0036] In some embodiments, the two binding domains of the single-chain antibody are connected by a linker, and wherein the linker may include, for example, a cysteine ​​or non-natural amino acid residue for binding to the antibody. 1 Site-specific conjugation.

[0037] In some embodiments, D can be selected from any DNA cross-linking agent, microtubule inhibitor, DNA alkylating agent, topoisomerase inhibitor, or a combination thereof.

[0038] In some embodiments, D can be selected from MMAE, MMAF, SN38, DM1, DM4, calicheamycin, pyrrolobenzodiazepines, duocarmycin or a derivative thereof, or a combination thereof, and the like.

[0039] In some embodiments, D is monomethyl auristatin E (MMAE, an anti-mitotic drug) or a derivative thereof; or SN38 (a potent topoisomerase I inhibitor) or a derivative thereof; or a combination thereof.

[0040] In another embodiment, D is MMAE and is linked to a self-immolative spacer, such as 4-aminobenzyl alcohol (PAB), and a trigger moiety, such as valine-citrulline.

[0041] In any of the above aspects and embodiments, the non-immunogenic polymer can be selected from polyethylene glycol (PEG), dextran, carbohydrate polymers, polyalkylene oxide, polyvinyl alcohol, hydroxypropyl methacrylamide (HPMA) and copolymers thereof. Preferably, the non-immunogenic polymer is polyethylene glycol, such as branched polyethylene glycol or linear polyethylene glycol. The total molecular weight of polyethylene glycol can be 5000 to 100,000 daltons, for example, 5000 to 80,000 daltons, 10,000 to 60,000 daltons and 20,000 to 40,000 daltons. Polyethylene glycol can be connected to the multifunctional part T through a permanent bond or a cleavable bond.

[0042] To form (L 1 ) a The site-specific conjugation functional group connected to protein A can be selected from thiol, maleimide, 2-pyridyl dithio variant, aromatic sulfone or vinyl sulfone, acrylate, bromo or iodoacetamide, azide, alkyne, dibenzocyclooctyl (DBCO), carbonyl, 2-amino-benzaldehyde or 2-amino-acetophenone group, hydrazide, oxime, potassium acyl trifluoroborate, O-carbamoylhydroxylamine, trans-cyclooctene, tetrazine, triarylphosphine, iodine borate, etc.

[0043] In some embodiments, (L 1 ) a One of the may comprise a linkage formed from an azide and an alkyne or from a maleimide and a thiol. In some embodiments, the alkyne may be dibenzocyclooctyl (DBCO).

[0044] In some embodiments, T may be lysine, P may be polyethylene glycol, y may be 1, and the alkyne may be dibenzocyclooctyl (DBCO).

[0045] In some embodiments, A may be derived from an azide-labeled monospecific or multispecific antibody or antigen-binding protein, including an antibody fragment, a single-chain antibody, a nanobody, or any antigen-binding fragment thereof, or a combination thereof, wherein the azide may be present in each (L 1 ) a In other embodiments, the A protein can be derived from a thiol-labeled monospecific or multispecific antibody or antigen-binding protein, including an antibody fragment, a single-chain antibody, a nanobody or any antigen-binding fragment thereof, or a combination thereof, wherein the thiol can be conjugated to an alkyne in each (L 1 ) a Conjugated with maleimide.

[0046] The above-mentioned antibody drug conjugate can be prepared according to a method comprising the following steps: (i) preparing a highly loaded non-immunogenic polymer drug conjugate having a terminal functional group that can be site-specifically conjugated to an antibody or protein or a modified form thereof; and (ii) site-specifically conjugating the non-immunogenic polymer drug conjugate to an antibody or protein or a modified structure thereof to form a compound of Formula Ia, Ib or Ic. In some embodiments, the antibody or protein can be modified with a small molecule linker prior to the conjugation step.

[0047] The present invention also provides a pharmaceutical preparation comprising the above antibody-drug conjugate, such as a PEGylated monospecific or bispecific single-chain antibody-drug conjugate that is monovalent or multivalent to an antigen, and a pharmaceutically acceptable carrier.

[0048] The present invention further provides a method of treating a disease in a subject in need thereof, comprising administering an effective amount of the above-mentioned antibody drug conjugate, such as a PEGylated monospecific or bispecific single chain antibody drug conjugate that is monovalent or multivalent to an antigen.

[0049] The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the drawings, the description, and the claims.

[0050] The present disclosure also provides the following embodiments.

[0051] Embodiment 1. Compound of formula (Ib)

[0052]

[0053] in:

[0054] P is a non-immunogenic polymer;

[0055] M is H or selected from C 1-50 Alkyl and aryl end-capping groups, wherein one or more carbons of the alkyl group may be optionally substituted with a heteroatom;

[0056] y is an integer selected from 1 to 10, such as 1 to 5, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0057] A is an antibody or an antigen-binding fragment thereof, and

[0058] T is a multifunctional small molecule linker moiety;

[0059] L 1 and L 2 each independently is a hetero- or homo-bifunctional linker;

[0060] a and b are each an integer selected from 0 to 10, such as 0 to 5, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0061] B is a branched linker, wherein each branch has an amino acid sequence or carbohydrate moiety connected to a self-immolative spacer, the cleavage of which by an enzyme triggers a self-immolative mechanism to release D, or each branch has a disulfide bond or a cleavable bond, the cleavage of which releases D or a derivative thereof;

[0062] D are each independently a cytotoxic small molecule or a peptide; and

[0063] n can be an integer selected from 1 to 25, for example, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 25, 10 to 20, 10 to 15, 15 to 25, 15 to 20, or 20 to 25, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25.

[0064] Embodiment 2. The compound of embodiment 1, wherein T is a trifunctional linker derived from a molecule having three functional groups selected from hydroxyl, amino, hydrazine, azide, olefin, alkyne, carboxyl (aldehyde, ketone, ester, carboxylic acid, anhydride, acyl halide), thiol, disulfide, nitrile, epoxide, imine, nitro and halide, and wherein T and (L 1 ) a The connection between T and (L 2 ) b The connections between them are the same or different.

[0065] Embodiment 3. The compound of Embodiment 2, wherein T is lysine or is derived from lysine.

[0066] Embodiment 4. The compound of any one of Embodiments 1 to 3, wherein L 1 The functional group at the end of the linker is capable of site-specific conjugation with A and is selected from thiol, maleimide, 2-pyridyl dithio variant, aromatic sulfone or vinyl sulfone, acrylate, bromo or iodoacetamide, azide, alkyne, dibenzocyclooctyl (DBCO), carbonyl, 2-amino-benzaldehyde or 2-amino-acetophenone group, hydrazide, oxime, potassium acyl trifluoroborate, O-carbamoylhydroxylamine, trans-cyclooctene, tetrazine, triarylphosphine, boronic acid and iodine.

[0067] Embodiment 5. The compound of any one of embodiments 1 to 4, wherein the antibody is a monospecific or multispecific full length antibody, a single chain antibody, a nanobody or an antigen binding domain thereof.

[0068] Embodiment 6. The compound of any one of embodiments 1 to 5, wherein the antibody is a monospecific single chain antibody.

[0069] Embodiment 7. The compound of embodiment 6, wherein the monospecific single chain antibody binds to a tumor associated antigen (TAA) such as Her2.

[0070] Embodiment 8. The compound of embodiment 7, wherein the monospecific single chain antibody has two binding domains that bind to Her2.

[0071] Embodiment 9. The compound of embodiment 8, wherein the monospecific single-chain antibody has the amino acid sequence shown in SEQ ID NO:2.

[0072] Embodiment 10. The compound of any one of embodiments 1 to 5, wherein the antibody is a bispecific antibody, such as a bispecific single chain antibody.

[0073] Embodiment 11. The compound of embodiment 10, wherein the two structural binding domains of the bispecific antibody bind to the same tumor-associated antigen (TAA), bind to two different TAAs, or bind to a TAA and an antigen expressed on T cells (e.g., a component of a T cell receptor) or NK cells.

[0074] Embodiment 12. The compound of embodiment 11, wherein the antibody is an anti-Her2 x anti-Her2 single chain bispecific antibody.

[0075] Embodiment 13. The compound of embodiment 12, wherein the antibody has the amino acid sequence shown in SEQ ID NO:1.

[0076] Embodiment 14. The compound of any one of embodiments 6 to 9, wherein the two binding domains of the monospecific single-chain antibody are connected by a linker, and wherein the linker comprises a moiety such as cysteine ​​or a non-natural amino acid residue for binding of the antibody to L 1 Site-specific conjugation.

[0077] Embodiment 15. The compound of any one of embodiments 10 to 13, wherein the two binding domains of the bispecific single chain antibody are connected by a linker, and wherein the linker comprises a moiety such as cysteine ​​or a non-natural amino acid residue for binding of the antibody to L 1 Site-specific conjugation.

[0078] Embodiment 16. The compound of any one of embodiments 14 to 15, wherein the unnatural amino acid is selected from the group consisting of a genetically encoded alkene lysine (e.g., N6-(hex-5-enoyl)-L-lysine), 2-amino-8-oxononanoic acid, m- or p-acetylphenylalanine, an amino acid containing a β-diketone side chain (e.g., 2-amino-3-(4-(3-oxobutanoyl)phenyl)propionic acid), (S)-2-amino-6-(((1R,2R)-2-azidocyclopentyloxy)carbonylamino)hexanoic acid, azidohomoalanine, a pyrrole-lysine analog N6-((prop-2-yn-1-oxy)carbonyl)-L-lysine, (S)-2-amino The invention relates to (S)-6-pentan-4-aminohexanoic acid, (S)-2-amino-6-((prop-2-ynyloxy)carbonylamino)hexanoic acid, (S)-2-amino-6-((2-azidoethoxy)carbonylamino)hexanoic acid, p-azidophenylalanine, p-azidophenylalanine, Nε-acryloyl-1-lysine, Nε-5-norbornene-2-oxycarbonyl-1-lysine, N-ε-(cyclooct-2-yn-1-oxy)carbonyl)-L-lysine, N-ε-(2-(cyclooct-2-yn-1-oxy)ethyl)carbonyl-L-lysine, and a genetically encoded tetrazine amino acid (e.g., 4-(6-methyl-s-tetrazin-3-yl)aminophenylalanine).

[0079] Embodiment 17. The compound of any one of embodiments 1 to 16, wherein D is selected from a DNA cross-linking agent, a microtubule inhibitor, a DNA alkylating agent, a topoisomerase inhibitor, or a combination thereof.

[0080] Embodiment 18. The compound of Embodiment 17, wherein D is selected from MMAE, MMAF, SN38, DM1, DM4, echinococcal toxin, pyrrolobenzodiazepines, duocarmycin or a derivative thereof, or a combination thereof.

[0081] Embodiment 19. The compound of embodiment 17, wherein D is selected from vinca alkaloids, laulimalide, taxanes, colchicine, tubulysin, Cryptophycin, Hemiasterlin, Cemadotin, Rhizoxin, Discodermolide, taccalonolide A or B or AF or AJ, taccalonolide AI-epoxide, CA-4, epothilones A and B, laulimalide, paclitaxel, docetaxel, doxorubicin, camptothecin, iSGD-1882, centanamycin, PNU-159682, uncialamycin, indole benzodiazepine dimer, β-amanitin, Amatoxin, thailanstatin or derivatives or analogs thereof, or combinations thereof.

[0082] Embodiment 20. The compound of any one of embodiments 1 to 19, wherein the non-immunogenic polymer is polyethylene glycol (PEG).

[0083] Embodiment 21. The compound of embodiment 20, wherein the polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

[0084] Embodiment 22. The compound of any one of Embodiments 20 to 21, wherein at least one end of the polyethylene glycol is capped with a methyl group or a low molecular weight alkyl group.

[0085] Embodiment 23. The compound of any one of Embodiments 20 to 22, wherein the total molecular weight of the polyethylene glycol is 100 to 80,000.

[0086] Embodiment 24. The compound of any one of embodiments 20 to 23, wherein the polyethylene glycol is linked to a trifunctional or tetrafunctional or any other cyclic or acyclic or acyclic multifunctional moiety T (eg lysine) via a permanent or cleavable bond.

[0087] Embodiment 25. Compound of formula (Ic)

[0088]

[0089] in:

[0090] P is a linear polyethylene glycol;

[0091] A is an antibody or an antigen-binding fragment thereof;

[0092] L 1 and L 2each independently is a bifunctional linker;

[0093] a and b are each an integer selected from 0 to 10, such as 0 to 5, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0094] B is a branched linker, wherein each branch has an amino acid sequence or carbohydrate moiety connected to a self-immolative spacer, the cleavage of which by an enzyme triggers a self-immolative mechanism to release D, or each branch has a disulfide bond or a cleavable bond, the cleavage of which releases D or a derivative thereof;

[0095] D are each independently a cytotoxic small molecule or a peptide;

[0096] n is an integer selected from 1 to 25, for example, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 25, 10 to 20, 10 to 15, 15 to 25, 15 to 20, or 20 to 25, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25.

[0097] Embodiment 26. The compound of Embodiment 25, wherein L 1 The functional group at the end of the linker is capable of site-specific conjugation with A and is selected from thiol, maleimide, 2-pyridyl dithio variant, aromatic sulfone or vinyl sulfone, acrylate, bromo or iodoacetamide, azide, alkyne, dibenzocyclooctyl (DBCO), carbonyl, 2-amino-benzaldehyde or 2-amino-acetophenone group, hydrazide, oxime, potassium acyl trifluoroborate, O-carbamoylhydroxylamine, trans-cyclooctene, tetrazine, triarylphosphine, boronic acid and iodine.

[0098] Embodiment 27. The compound of any one of embodiments 25 to 26, wherein the antibody is a monospecific or multispecific full length antibody, a single chain antibody, a nanobody or an antigen binding domain thereof.

[0099] Embodiment 28. The compound of embodiment 27, wherein the antibody is a monospecific single chain antibody, optionally, the monospecific single chain antibody binds to a tumor associated antigen (TAA) such as Her2.

[0100] Embodiment 29. The compound of embodiment 28, wherein the monospecific single chain antibody has two binding domains that bind to Her2.

[0101] Embodiment 30. The compound of embodiment 29, wherein the monospecific single chain antibody has the amino acid sequence shown in SEQ ID NO:2.

[0102] Embodiment 31. The compound of embodiment 27, wherein the antibody is a bispecific antibody, such as a bispecific single chain antibody.

[0103] Embodiment 32. The compound of embodiment 31, wherein the two binding domains of the bispecific antibody bind to the same tumor-associated antigen (TAA), bind to two different TAAs, or bind to a TAA and an antigen expressed on T cells (e.g., a component of a T cell receptor) or NK cells.

[0104] Embodiment 33. The compound of embodiment 32, wherein the antibody is an anti-Her2 x anti-Her2 single chain bispecific antibody.

[0105] Embodiment 34. The compound of embodiment 33, wherein the antibody has the amino acid sequence shown in SEQ ID NO:1.

[0106] Embodiment 35. The compound of any one of embodiments 28 to 30, wherein the two binding domains of the monospecific single-chain antibody are connected by a linker, and wherein the linker comprises a moiety such as cysteine ​​or a non-natural amino acid residue for binding of the antibody to L 1 Site-specific conjugation.

[0107] Embodiment 36. The compound of any one of embodiments 31 to 34, wherein the two binding domains of the bispecific single chain antibody are connected by a linker, and wherein the linker comprises a moiety such as cysteine ​​or a non-natural amino acid residue for binding of the antibody to L 1 Site-specific conjugation.

[0108] Embodiment 37. The compound of any one of embodiments 35 to 36, wherein the compound is used for the antibody and L 1The non-natural amino acid residues for site-specific conjugation are selected from the group consisting of genetically encoded olefin lysine (e.g., N6-(hex-5-enoyl)-L-lysine), 2-amino-8-oxonanoic acid, m- or p-acetylphenylalanine, amino acids containing a β-diketone side chain (e.g., 2-amino-3-(4-(3-oxobutanoyl)phenyl)propionic acid), (S)-2-amino-6-(((1R, 2R)-2-azidocyclopentyloxy)carbonylamino)hexanoic acid, azidohomoalanine, pyrrole-lysine analogs N6-((prop-2-yn-1-oxy)carbonyl)-L-lysine, (S)-2-amino-6-pent-4-amino The invention relates to amino acids, (S)-2-amino-6-((prop-2-ynyloxy)carbonylamino)hexanoic acid, (S)-2-amino-6-((2-azidoethoxy)carbonylamino)hexanoic acid, p-azidophenylalanine, p-azidophenylalanine, Nε-acryloyl-1-lysine, Nε-5-norbornene-2-oxycarbonyl-1-lysine, N-ε-(cyclooct-2-yn-1-oxy)carbonyl)-L-lysine, N-ε-(2-(cyclooct-2-yn-1-oxy)ethyl)carbonyl-L-lysine, and genetically encoded tetrazine amino acids (such as 4-(6-methyl-s-tetrazin-3-yl)aminophenylalanine).

[0109] Embodiment 38. The compound of any one of embodiments 25 to 37, wherein D is selected from a DNA cross-linking agent, a microtubule inhibitor, a DNA alkylating agent, a topoisomerase inhibitor, or a combination thereof.

[0110] Embodiment 39. Any one of the compounds of Embodiment 38, wherein D is selected from MMAE, MMAF, SN38, DM1, DM4, echinococcal toxins, pyrrolobenzodiazepines, duocarmycins or derivatives thereof, or combinations thereof.

[0111] Embodiment 40. Any one of the compounds of Embodiment 38, wherein D is selected from a vinca alkaloid, laulimalide, a taxane, colchicine, tubulysin, Cryptophycin, Hemiasterlin, Cemadotin, Rhizoxin, Discodermolide, taccalonolide A or B or AF or AJ, taccalonolide AI-epoxide, CA-4, epothilones A and B, laulimalide, paclitaxel, docetaxel, doxorubicin, camptothecin, iSGD-1882, centanamycin, PNU-159682, uncialamycin, an indolebenzodiazepine dimer, β-amanitin, Amatoxin, thailanstatin or a derivative or analog thereof, or a combination thereof.

[0112] Embodiment 41. The compound of any one of Embodiments 25 to 40, wherein the total molecular weight of the polyethylene glycol is 100 to 80,000.

[0113] Embodiment 42. The compound of any one of Embodiments 1 to 41, wherein L 1 and L 2 Each independently selected from:

[0114] -(CH 2 ) a XY(CH 2 ) b -,

[0115] -X(CH 2 ) a O(CH 2 CH 2 O) c (CH 2 ) b Y-,

[0116] -(CH 2 ) a Heterocyclyl-,

[0117] -(CH 2 ) a X-,

[0118] -X(CH 2 ) a Y-,

[0119] -W 1 -(CH 2 )a C(O)NR 1 (CH 2 ) b O(CH 2 CH 2 O) c (CH 2 ) d C(O)-,

[0120] -C(O)(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c W 2 C(O)(CH 2 ) d NR 1 -,

[0121] -W 3 -(CH 2 ) a C(O)NR 1 (CH 2 ) b O(CH 2 CH 2 O) c (CH 2 ) d W 2 C(O)(CH 2 ) e C(O)-,

[0122] wherein a, b, c, d and e are each independently an integer selected from 0 to 25, for example, 0 to 20, 0 to 15, 0 to 10, 0 to 5, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 25, 10 to 20, 10 to 15, 15 to 25, 15 to 20 or 20 to 25, for example 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25; and X and Y are each independently selected from C(═O), NR 1 , S, O, CR 2 R 3 or none; R 1 and R 2 independently represent hydrogen, C 1-10 Alkyl or (CH 2 ) 1-10 C(=O);W 1 and / or W 3Derived from a maleimido-based moiety, W 2 represents a triazolyl or tetrazolyl containing group; the heterocyclic group is selected from a maleimido derived moiety or a tetrazolyl-based or triazolyl-based moiety.

[0123] Embodiment 43. The compound of any one of Embodiments 1 to 41, wherein L 1 and L 2 Each independently selected from:

[0124]

[0125] wherein n and m are integers and are independently selected from 0 to 20, such as 0 to 15, 0 to 10, 0 to 5, 5 to 20, 5 to 15, 5 to 10, 10 to 20, 10 to 15 or 15 to 20, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0126] Embodiment 44. A compound of any one of embodiments 1 to 43, wherein the branched linker B comprises an extended spacer, a trigger unit, a self-immolative spacer or any combination thereof, optionally wherein the trigger unit is an amino acid sequence or a β-glucuronide or β-galactoside trigger portion that can be cleaved by an enzyme, such as cathepsin B, plasmin, matrix metalloproteinase (MMP), β-glucuronidase, β-galactosidase; a pH-sensitive linker that can release drug D or its derivative under acidic pH conditions; or a disulfide linker that can release drug D or its derivative by glutathione, a thioredoxin family member (WCGH / PCK) or a sulfhydryl reductase.

[0127] Embodiment 45. The compound of embodiment 44, wherein the branched linker B is selected from

[0128]

[0129]

[0130] in:

[0131] a, b, c, d, e and f are each an integer and are independently selected from 1 to 25, for example, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 25, 10 to 20, 10 to 15, 15 to 25, 15 to 20 or 20 to 25, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25;

[0132] (A)n is an amino acid sequence trigger unit, such as Val-Cit, al-Ala, Val-Lys, Phe-Lys, Phe-Cit, Phe-Arg, Phe-Ala, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, D-Phe-LPhe-Lys, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Gly-Phe-Leu-Gly, or Ala-Leu-Ala-Leu;

[0133] PAB is p-aminobenzyl alcohol;

[0134] Ex are each an extended spacer comprising a linker chain, independently selected from:

[0135] -NR 1 (CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z C(O)-,

[0136] -C(O)(CH 2 ) x NR 1 -,

[0137] -NR 1 (CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z NR 2 -,

[0138] -NR 1 (CH 2 ) x NR 2 -,

[0139] -NR 1 (CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z O-,

[0140] -O(CH 2 ) x NR 1 -,

[0141] -C(O)(CH 2 ) x O-,

[0142] -O(CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z C(O)-,

[0143] -C(O)(CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z C(O)-,

[0144] -C(O)(CH 2 ) x C(O)-,

[0145] or none,

[0146] wherein x, y and z are each an integer and are independently selected from 0 to 25, e.g., 0 to 20, 0 to 15, 0 to 10, 0 to 5, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 25, 10 to 20, 10 to 15, 15 to 25, 15 to 20 or 20 to 25, or 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25; R 1 and R 2 independently represents hydrogen or C 1-10 alkyl.

[0147] Embodiment 46. Any one of embodiments 1 to 43, wherein the branched linker B is selected from

[0148]

[0149] Embodiment 47. A compound of Embodiment 1 selected from the following formula:

[0150]

[0151]

[0152]

[0153] or a pharmaceutically acceptable salt thereof.

[0154] Embodiment 48. A compound of Embodiment 25 selected from the formula:

[0155]

[0156] Embodiment 49. A method for preparing a compound of any one of Embodiments 1 to 48, comprising:

[0157] a) a step of preparing a non-immunogenically modified (e.g. PEGylated) drug conjugate having free functional groups for site-specific conjugation;

[0158] b) a step of site-specifically conjugating a non-immunogenic modified (eg, PEGylated) drug conjugate to the antibody to provide a compound of formula (Ib) or (Ic).

[0159] Embodiment 50. A pharmaceutical preparation comprising an effective amount of a compound according to any one of embodiments 1 to 48 and a pharmaceutically acceptable salt, carrier or excipient.

[0160] Embodiment 51. A compound according to any one of Embodiments 1 to 48 for use in the treatment of a cancer selected from breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, kidney cancer, bladder cancer, stomach cancer, colon cancer, colorectal cancer, salivary gland cancer, thyroid cancer and endometrial cancer.

[0161] Embodiment 52. A compound of any one of Embodiments 1 to 48, for use in combination with an effective amount of another anticancer agent, an immunosuppressant, for treating a cancer selected from breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, kidney cancer, bladder cancer, stomach cancer, colon cancer, colorectal cancer, salivary gland cancer, thyroid cancer, and endometrial cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0162] Figure 1 The reaction scheme for the preparation of branched linker intermediate compound 7 described in Example 1 is schematically illustrated.

[0163] Figure 2 The reaction scheme for the preparation of compound 14Val-Cit-PAB-MMAE described in Example 1 is schematically illustrated.

[0164] Figure 3 Schematic illustration of the preparation of the compound 1930kmPEG-Lys(Mal)-(Val-Cit-PAB-MMAE) described in Example 1 4 reaction scheme.

[0165] Figure 4Schematic illustration of the preparation of compound 2030kmPEG-Lys(SCAHer2 / SCAHer2)-(Val-Cit-PAB-MMAE) described in Example 3 4 reaction scheme.

[0166] Figure 5 The reaction scheme for preparing compound 7 Val-Cit-PABC-MMAE in Example 4 is schematically illustrated.

[0167] Figure 6 The reaction scheme for preparing compound 13 (branched linker B with 2XMMAE) in Example 5 is schematically illustrated.

[0168] Figure 7 The reaction scheme for preparing compound 18 (branched linker B with 2XMMAE) in Example 6 is schematically illustrated.

[0169] Figure 8 The reaction scheme for preparing compound 22 (branched linker B with 4XMMAE) in Example 7 is schematically illustrated.

[0170] Fig. 9 The reaction scheme for preparing compound 27 (branched linker B with 4XMMAE) in Example 8 is schematically illustrated.

[0171] Fig.10 The reaction scheme for preparing compound 32 (30 kmPEG(maleimide)-2MMAE) in Example 9 is schematically illustrated.

[0172] Fig.11 The reaction scheme for preparing compound 35 (20 kmPEG(maleimide)-4MMAE) in Example 10 is schematically illustrated.

[0173] Fig.12 The reaction scheme for preparing compound 39 (maleimide-20mPEG-4MMAE) in Example 11 is schematically illustrated.

[0174] Fig.13 The reaction scheme for preparing Compound 41 (DBCO-20mPEG-4MMAE) in Example 12 is schematically illustrated.

[0175] Fig.14 SDS-PAGE and SEC-HPLC analysis of compound 42 (SCAHer2II×SCAHer2IV) purified in Example 13 are shown.

[0176] Fig.15The reaction scheme and SDS-PAGE analysis for preparing compound 43 [30 kmPEG-(SCAHer2II / SCAHer2IV)-2MMAE] in Example 14 are schematically illustrated.

[0177] Fig.16 The reaction scheme and SDS-PAGE analysis for preparing compound 44 [SCAHer2II / SCAHer2IV-20kPEG-4MMAE] in Example 15 are schematically illustrated.

[0178] Fig.17 It was demonstrated in Example 16 that compound 43 (JY201) had potent in vitro cytotoxicity.

[0179] Fig.18 It was demonstrated in Example 16 that compound 44 (JY201b) induced in vitro cytotoxicity against tumor cells more effectively than T-DM1 at equal loading.

[0180] Fig.19 It is demonstrated in Example 14 that PEGylated BsADC 43 (JY201) exhibits increased target cell internalization.

[0181] Fig. 20 It is demonstrated in Example 15 that PEGylated BsADC 43 (JY201) is retained in target cells after internalization.

[0182] Fig.21 It was demonstrated in Example 16 that PEGylated BsADC 43 (JY201) was not toxic to megakaryocytes. DETAILED DESCRIPTION OF THE INVENTION

[0184] In the present invention, a pegylated monospecific or multispecific antibody drug conjugate is provided. According to the present invention, it is not necessary to destroy two or more disulfide bonds of an antibody to obtain a high DAR, and a homogeneous ADC can be achieved, which has significant advantages over heterogeneous ADCs in terms of toxicity, efficacy, regulatory management and manufacturing, especially in the manufacturing of multispecific ADCs.

[0185] In addition, the present invention provides a novel structural form of a pegylated monospecific or bispecific single-chain antibody drug conjugate, which not only shows no toxicity to megakaryocytes or other normal cells and increases the therapeutic window, but also enhances the anti-tumor effect of the conjugate by increased internalization, and has a relatively small size of single-chain antibody molecules to achieve deep penetration into solid tumors. Therefore, the present invention solves the problems in current ADC technology and improves cancer treatment through novel pegylated monospecific or multispecific single-chain antibody drug conjugates.

[0186] I. Conjugates

[0187] In one aspect of the present invention, there is provided a compound of formula (Ia):

[0188]

[0189] In this compound, P can be a non-immunogenic polymer. T can be a multifunctional part, such as a trifunctional small molecule linker part, and has at least one functional group that can be site-specifically conjugated to an antibody or protein. A can be any monospecific or multispecific antibody or protein, such as a full-length antibody, a single-chain antibody, a nanobody, or any antigen-binding fragment thereof, or a combination thereof. D can be any cytotoxic small molecule or peptide (n=1 to 25), and each D can be the same or different.

[0190] In particular, one aspect of the present invention provides a conjugate of formula Ib or Ic:

[0191]

[0192] In the conjugate of Formula Ib or Formula Ic, P may be a non-immunogenic polymer, such as polyethylene glycol;

[0193] M can be H or selected from C 1-50 Alkyl and aryl end-capping groups, wherein one or more carbons of the alkyl group are optionally substituted with heteroatoms;

[0194] y may be an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0195] T may be a moiety having two or more functional groups, wherein T and (L 1 ) a The connection between T and (L 2 ) b The connections between can be the same or different;

[0196] L 1 and L 2 can each independently be a bifunctional linker;

[0197] a and b can each be an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0198] B can be a branched linker, wherein each branch can contain an extended spacer, a trigger unit, a self-immolative spacer or any combination thereof, wherein the trigger unit can be an amino acid sequence or a β-glucuronide or β-galactoside trigger portion that can be cleaved by an enzyme (e.g., cathepsin B, plasmin, matrix metalloproteinase (MMP), β-glucuronidase, β-galactosidase); a pH-sensitive linker that can release drug D or its derivatives under acidic pH conditions; or a disulfide bond linker that can release drug D or its derivatives by glutathione, a thioredoxin family member (WCGH / PCK) or a sulfhydryl reductase.

[0199] A can be any monospecific or multispecific antibody or antigen-binding protein, including an antibody fragment, a single-chain antibody, a nanobody, or any antigen-binding fragment, which is monovalent or multivalent against an antigen;

[0200] D can be any cytotoxic small molecule or peptide or its derivative and can be released from B by enzymatic cleavage and / or autolytic mechanism or pH-induced hydrolysis; each D can be the same or different;

[0201] n may be an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.

[0202] In some embodiments, each branch of B comprises a trigger moiety, such as an amino acid sequence or a disulfide moiety or a β-glucoside or a β-galactosamine, which is linked to the drug D through a self-immolative spacer or directly to the drug D. Examples of self-immolative spacers include, but are not limited to, the following:

[0203]

[0204] Where R 1 , R 2 , R 3 , R 4 Can be H or C 1-10 In such embodiments, D can be any small molecule or peptide drug or derivative thereof containing an active O or N or S functional group.

[0205] In some embodiments, each branch of B may include a pH-sensitive linker that can release drug D or its derivative under acidic pH conditions at the tumor site and / or inside tumor cells. Examples of acid-sensitive linkers include, but are not limited to, the following forms:

[0206] -CR 1 =N-NR 1 -、-CR 1=NO-, -CR 1 =N-NR 2 -CO-, -N=N-CO-, -OCOO-, -NR 1 -COO-.

[0207] In some embodiments, each branch of B may contain a disulfide bond linker that can be enzymatically cleaved, for example by glutathione, thioredoxin family members (WCGH / PCK) or sulfhydryl reductase, to release drug D or its derivative at the tumor site and / or inside the tumor cell.

[0208] In some embodiments, A is a single chain bispecific antibody capable of binding to two different epitopes on two Her2 antigens (SCAHer2IIxSCAHer2IV).

[0209] In some embodiments, the amino acid sequence of SCAHer2IIxSCAHer2IV can be:

[0210]

[0211] In some embodiments, A is a single chain anti-Her2 x anti-Her2 monospecific antibody capable of binding to two identical epitopes on two Her2 antigens.

[0212] In some embodiments, the amino acid sequence of SCAHer2IV / SCAHer2IV may be:

[0213]

[0214]

[0215] In some embodiments, A is a single chain bispecific antibody capable of binding to two different antigens Her2 and Her3 (SCAHer2xSCAHer3).

[0216] In some embodiments, the amino acid sequence of SCAHer2IVxSCAHer3 may be:

[0217]

[0218] In some embodiments, A is a single chain bispecific antibody that binds to Met1 and Met2 (SCAc-Met1xSCAc-Met2).

[0219] In some embodiments, the amino acid sequence of SCAc-Met1xSCAc-Met2 may be:

[0220]

[0221]

[0222] In some embodiments, D can be released at the tumor site or inside tumor cells via enzymatic and / or autolytic mechanisms or pH-induced hydrolysis.

[0223] In some embodiments, D can be selected from any DNA cross-linking agent, microtubule inhibitor, DNA alkylating agent, topoisomerase inhibitor, or a combination thereof.

[0224] In some embodiments, D can be selected from auristatins (MMAE, MMAF), vinca alkaloids, laulimalide, taxanes, colchicine, maytansine (DM1, DM4), tubulysin, Cryptophycin, Hemiasterlin, Cemadotin, Rhizoxin, Discodermolide, taccalonolide A or B. or AF or AJ, radix ketolide AI-epoxide, CA-4, epothilone A and B, laulimalide, paclitaxel, docetaxel, pyrrolobenzodiazepines, duocarmycin, doxorubicin, calicheamicin, camptothecin, SN38, iSGD-1882, centanamycin, PNU-159682, uncialamycin, indolebenzodiazepine dimer, β-amanitin, amatoxin, thailanstatin or its derivatives or analogs, or a combination thereof.

[0225] In some embodiments, D is monomethyl auristatin E (MMAE, an anti-mitotic drug) or a derivative thereof; or SN38 (a potent topoisomerase I inhibitor) or a derivative thereof; or a combination thereof.

[0226] In another embodiment, D is linked to a self-immolative spacer such as 4-aminobenzyl alcohol (PAB) and a trigger moiety such as valine-citrulline to form Val-Cit-PAB-D.

[0227] In one aspect of the present invention, a method for preparing a PEGylated drug conjugate is provided, which can be site-specifically conjugated to a protein or antibody, including an antibody fragment or a single-chain monospecific or multispecific antibody. In another aspect of the present invention, a method for preparing a PEGylated single-chain BsADC is provided.

[0228] In order to synthesize PEGylated single-chain BsADC, the coding sequence of 1 to 5-valent monospecific single-chain antibody or single-chain bispecific antibody or a vector carrying the coding sequence can be synthesized and introduced into, for example, a CHO expression system. The protein can be expressed and purified as previously described (WO2018075308).

[0229] To synthesize PEGylated drug conjugates with side chains containing site-specific conjugation functional groups, the terminal functional groups of polyethylene glycol, such as hydroxyl or carboxyl groups, can be activated and conjugated with trifunctional small molecule moieties such as Boc or Fmoc protected lysine to form terminally branched heterobifunctional polyethylene glycol. The newly formed carboxyl group can be coupled with a branching spacer to form PEG-Lys(Boc)-B. After coupling, the protecting groups can be removed and the unprotected PEGylated branched linker can be coupled with a small molecule linker with site-specific conjugation functional groups such as maleimide or DBCO to form PEG-Lys(Mal)-B or PEG-Lys(DBCO)-B. Such as PEG-lys(Mal)-B-(Val-Cit-PAB-MMAE) n or PEG-lys(DBCO)-B-(Val-Cit-PAB-MMAE) n The PEGylated drug conjugate can be prepared by coupling reaction of PEG-Lys(Mal)-B or PEG-Lys(DBCO)-B with Val-Cit-PAB-MMAE, wherein n is an integer such as 2. The last step of the synthesis is site-specific conjugation of the PEGylated drug conjugate with a thiol- or azide-labeled single-chain bispecific antibody.

[0230] Alternatively, in order to synthesize a PEGylated drug conjugate having a side chain with a site-specific conjugation functional group, the terminal functional group of the polyethylene glycol, such as a hydroxyl or carboxyl group, can be activated after removing the protecting group and conjugated with a trifunctional small molecule portion, such as a Boc or Fmoc protected lysine, to form a terminally branched heterobifunctional polyethylene glycol. The deprotected polyethylene glycol compound can be coupled with a small molecule linker having a site-specific conjugation functional group, such as maleimide or DBCO, to form PEG-Lys(Mal)-OH or PEG-Lys(DBCO)-OH. PEG-Lys(Mal)-OH or PEG-Lys(DBCO)-OH can then be coupled with a branching portion, wherein each branch is connected to the drug D through an extended spacer, a trigger unit and / or a self-degrading spacer to form a PEGylated drug conjugate, such as PEG-lys(Mal)-B-(Val-Cit-PAB-MMAE) n Or PEG-lys(DBCO)-B-(Val-Cit-PAB-MMAE) n, wherein n is an integer such as 2. The final step of the synthesis is site-specific conjugation of the PEGylated drug conjugate to a thiol- or azide-labeled single-chain bispecific antibody to form compounds of Formulas Ia and Ib. Alternatively, a similar method can be used to synthesize PEGylated drug conjugates from commercially available heterobifunctional polyethylene glycol to form compounds of Formula Ic.

[0231] II. Polyethylene glycol linker

[0232] In one embodiment of the present invention, the polyethylene glycol may be of the formula:

[0233]

[0234] In this formula, n can be an integer from 1 to about 2300, preferably to provide a polymer having a total molecular weight of 5000 to 40000 or greater (if desired). M can be H, methyl or other low molecular weight alkyl. Non-limiting examples of M include H, methyl, ethyl, isopropyl, propyl, butyl or F. 1 (CH 2 )q 2 . F and F 1 It can be independently a terminal functional group, such as hydroxyl, carboxyl, thiol, halide, amino, etc., which can be functionalized, activated and / or conjugated with a small molecule spacer or linker. q and m can be any integer from 0 to 10.

[0235] In another embodiment of the present invention, the method can also be carried out with another alternative branched polyethylene glycol. The branched polyethylene glycol can be of the formula:

[0236]

[0237] In this formula, PEG is polyethylene glycol. m can be an integer from 2 to 10, preferably to provide a branched polyethylene glycol with a total molecular weight of 5000 to 80000 or greater (if necessary). M can be a methyl group or other low molecular weight alkyl group. L can be a functional linking portion connecting two or more polyethylene glycols. Non-limiting examples of such linking portions are: any amino acid, such as glycine, alanine, lysine, or 1,3-diamino-2-propanol, triethanolamine, any 5-membered or 6-membered aromatic or aliphatic ring connected to two or more functional groups. S is any non-cleavable spacer. F can be a terminal functional group, such as a hydroxyl, carboxyl, thiol, amino group. i is 0 or 1. When i is equal to 0, the formula is as follows:

[0238]

[0239] Wherein: the definitions of the variables of PEG, m, M or L are the same as above.

[0240] The method of the present invention can also be carried out with alternative polymers, such as dextran, carbohydrate polymers, polyalkylene oxides, polyvinyl alcohol or other similar non-immunogenic polymers, whose end groups can be functionalized or activated. The above list is illustrative only and is not intended to limit the types of non-antigenic polymers suitable for use herein.

[0241] III. Trifunctional Linker T

[0242] T represents a trifunctional linker, which is connected with P, (L 1 ) a and (L 2 ) b Connect. T can be derived from a molecule with any combination of three functional groups, and the non-limiting examples of the functional groups include hydroxyl, amino, hydrazine, azide, olefin, alkyne, carboxyl (aldehyde, ketone, ester, carboxylic acid, anhydride, acyl halide), thiol, disulfide, nitrile, epoxide, imine, nitro and halide. The functional groups in the trifunctional linker can be the same or different. In some embodiments, one or two of the functional groups can be protected to achieve selective conjugation with other reactive ligands. Various protecting groups are known in the art, including the protecting groups shown in "Advanced Organic Chemistry" (3rd edition, 1985, Wiley and Sons, New York) compiled by March, for example. Before or after T and another reactive ligand react, the functional group can also be converted into other groups. For example, a hydroxyl group can be converted into a methanesulfonic acid (ester) or toluenesulfonic acid (ester) group. Halides can be replaced by azido. The acidic functional group of T can be converted into an alkyne functional group by coupling with an amino group containing a terminal alkyne.

[0243] In exemplary embodiments, T is derived from lysine, 1,3-diamino-2-propanol or triethanolamine. One or more functional groups on these molecules can be protected for selective reaction. In some embodiments, T is derived from Boc-protected lysine.

[0244] IV. Bifunctional Linker L 1 and L 2

[0245] Connector L 1 and L 2 All of them include independently selected from (CH 2 ) a XY(CH 2 ) b -,-X(CH 2 ) a O(CH 2 CH 2 O) c (CH 2 ) bY-,-(CH 2 ) a Heterocyclyl-,-(CH 2 ) a X- and -X(CH 2 ) a Y-linker chain, wherein a, b and c are each an integer selected from 0 to 25, including all subunits; X or Y is independently selected from C (= O), NR 1 , S, O, CR 2 R 3 or none; R 1 , R 2 and R 3 Represents hydrogen, C 1-10 Alkyl or (CH 2 ) 1-10 C(=O).

[0246] Connector L 1 and L 2 The heterocyclic linking group within the molecule (whether it is in an internal position or in a terminal position) can be derived from a maleimido-based moiety. Non-limiting examples of suitable precursors include N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC), N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-amidinohexanoate) (LC-SMCC), κ-maleimidoundecanoic acid N-succinimidyl ester (KMUA), γ-maleimidobutyric acid N-succinimidyl ester (GMBS), ε-maleimidohexanoic acid N- The hydroxysuccinimide esters are EMCS, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-(α-maleimidoacetoxy)-succinimide ester (AMAS), succinimidyl-6-(β-maleimidopropionamide) hexanoate (SMPH), N-succinimidyl 4-(p-maleimidophenyl)-butyrate (SMPB), and N-(p-maleimidophenyl) isocyanate (PMPI).

[0247] In some other non-limiting exemplary embodiments, each linker unit can also be derived from a haloacetyl-based moiety selected from N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), N-succinimidyl iodoacetate (SIA), N-succinimidyl bromoacetate (SBA) or N-succinimidyl 3-(bromoacetamido) propionate (SBAP).

[0248] Alternatively, the heterocyclic linking group of the linker can be a tetrazolyl or triazolyl group, which is formed by conjugating different linker moieties such as DBCO and azide. Thus, the heterocyclic group serves as a point of attachment.

[0249] In some embodiments, (L 1 ) a and (L 2 ) b Each can contain:

[0250] -X 1 -(CH 2 ) a C(O)NR(CH 2 ) b O(CH 2 CH 2 O) c (CH 2 ) d C(O)- or

[0251] -C(O)(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c X 2 C(O)(CH 2 ) d NR- or

[0252] -X 3 -(CH 2 ) a C(O)NR(CH 2 ) b O(CH 2 CH 2 Q) c (CH 2 ) d X 2 C(O)(CH 2 ) e C(O)-,

[0253] Where X 1 , X 2 and X 3 may be the same or different and independently represent a heterocyclic group;

[0254] a, b, c, d and e are each an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25; and

[0255] R represents hydrogen or C 1-10 alkyl.

[0256] In some embodiments, X 1 and / or X3 Derived from a maleimido-based moiety. In some embodiments, X 2 R represents a group containing a triazolyl or tetrazolyl. In some embodiments, R represents hydrogen. In some embodiments, a, b, c, d and e are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

[0257] In some exemplary embodiments, (L 1 ) a and (L 2 ) b Can be selected from:

[0258]

[0259] wherein n and m are integers and are independently selected from 0 to 20.

[0260] V. With branch connector B

[0261] The branched connector B may include a branching unit, an extension spacer, a trigger unit, a self-immolative spacer, or any combination thereof.

[0262] In some embodiments, the branching units comprise structures that can be independently selected from the following:

[0263]

[0264] X, Y, Z, W = C(O), NR 1 NR 2 , O, N or None

[0265] a, b, c = 0 to 10

[0266] R 1 and R 2 independently represents hydrogen or a C1-10 alkyl group.

[0267] In other embodiments, the branching units include structures that can be independently selected from the following:

[0268]

[0269] X, Y, Z, U, V, W=C(O), NR 1 NR 2 , O, N or None

[0270] a, b, c, d, e = 0 to 10

[0271] R 1 and R 2 independently represents a hydrogen atom or a C1-10 alkyl group.

[0272] In some embodiments, the extended spacer in each branch comprises a linker chain, which can be independently selected from:

[0273] -X(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c Y-,-X(CH 2 ) a Y-,

[0274] or any combination thereof, wherein a, b and c are each an integer selected from 0 to 25, including all subunits; X and Y can be independently selected from NR 1 NR 2 , C(O), O or none; R 1 and R 2 independently represents hydrogen or C 1-10 alkyl.

[0275] In other embodiments, the trigger unit includes any amino acid sequence or any carbohydrate moiety or disulfide or any cleavable bond that can be cleaved enzymatically or chemically.

[0276] In some embodiments, the self-immolative spacer comprises a structure that can be selected from the group consisting of:

[0277]

[0278] Where R 1 , R 2 , R 3 and R 4 independently represents hydrogen or C 1-10 X and Y can be NH or O or S, c is selected from 1 or 2.

[0279] In some embodiments, the self-immolative spacer is

[0280]

[0281] In some embodiments, the branched connector B can be selected from:

[0282]

[0283]

[0284]

[0285] in:

[0286] a, b, c, d, e and f are each an integer selected from 1 to 25;

[0287] (A) n is an amino acid sequence trigger unit, each A is an independent amino acid, and n is any integer from 1 to 25;

[0288] PAB is p-aminobenzyl alcohol;

[0289] Ex is an extended spacer comprising a linker chain and can be independently selected from:

[0290] -NR 1 (CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)-,

[0291] -C(O)(CH 2 ) a NR 1 -,

[0292] -NR 1 (CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c NR 2 -, NR 1 (CH 2 ) x O(CH 2 CH 2 O) y (CH 2 ) z NR 2 -,

[0293] -NR 1 (CH 2 ) a NR 2 -,-NR 1 (CH 2 ) x NR 2 -,

[0294] -NR 1 (CH 2 ) a O(CH 2 CH 2 O) b (CH2 ) c O-, -NR 1 (CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)-,

[0295] -O(CH 2 ) a NR 1 -,

[0296] -C(O)(CH 2 ) a O-,

[0297] -O(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)--NR1(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)-,

[0298] -C(O)(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)-,-NR1(CH 2 ) a O(CH 2 CH 2 O) b (CH 2 ) c C(O)-,

[0299] -C(O)(CH 2 ) a C(O)-,

[0300] or none;

[0301] wherein a, b and c are each an integer selected from 0 to 25, including all subunits; R 1 and R 2 independently represents hydrogen or C1-10 alkyl.

[0302] In other embodiments, the amino acid sequence trigger unit can be Val-Cit, al-Ala, Val-Lys, Phe-Lys, Phe-Cit, Phe-Arg, Phe-Ala, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, D-Phe-LPhe-Lys, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Gly-Phe-Leu-Gly, or Ala-Leu-Ala-Leu; or protected forms thereof.

[0303] For preferred embodiments, the amino acid sequence may be Val-Cit, Phe-Lys or Val-Lys.

[0304] In some exemplary embodiments, the branched connector B may be selected from:

[0305]

[0306] VI. Linking Group

[0307] The different parts of the conjugates of the present invention can be connected by various chemical linkages. Examples include, but are not limited to, amides, esters, disulfide bonds, ethers, amino groups, carbamates, hydrazines, thioethers, and carbonates. For example, the terminal hydroxyl group of the polyethylene glycol moiety (P) can be activated and then coupled with lysine (T) to provide the desired connection point between P and T of Formula Ia or Ib. T and L 1 Between or T and L 2 Between or L 2 The linker between L and B may be an amide. 2 between the amino group of lysine (T) or the carboxyl group of L 1 between the carboxyl group of T and the amino group of L 2 The reaction between the carboxyl group of A and the amino group of B produces. Depending on the desired properties of the conjugate, the antibody portion (A) and the adjacent linker L may also be 1 A suitable linking group is introduced between any two amino acids or between an amino acid and p-aminobenzyl alcohol.

[0308] In some embodiments, the linking group between the different parts of the conjugate can be derived from the coupling of a pair of functional groups that have inherent chemical affinity or selectivity to each other. These types of coupling or cyclization allow site-specific conjugation to introduce protein or antibody parts. Non-limiting examples of functional groups that cause site-specific conjugation include thiols, maleimides, 2'-pyridyl dithio variants, aromatic sulfones or vinyl sulfones, acrylates, bromo or iodoacetamides, azides, alkynes, dibenzocyclooctyl (DBCO), carbonyls, 2-amino-benzaldehyde or 2-amino-acetophenone groups, hydrazides, oximes, acyl trifluoroborate potassium, O-carbamoylhydroxylamine, trans-cyclooctene, tetrazines, triarylphosphines, boric acid, alkynes.

[0309] VII. Cytotoxic Compound D

[0310] In some embodiments, D may include, but is not limited to, maytansine (DM1, DM4) (US 5208020; US 5416064; EP 0425235), auristatin derivatives such as monomethyl auristatin E (MMAE) and F (MMAF) (US 5635483; US 5780588; US 7498298), pyrrolobenzodiazepines, cemadotin, SN38, scutellariae, radix scutellariae A or B or AF or AJ, radix scutellariae AI-epoxide, CA-4, vinca alkaloids, iSGD-1882, indole benzodiazepine dimer, uncialamycin, centanamycin, laulimalide, dolastatin, talanstatins, amatoxin, beta-amanitin, hemiacetyl, duocarmycin, PNU-159682, colchicine, tubulysin, calicheamicin or its derivatives (US Pat. No. 5,712,374; US Pat. No. 5,714,586; US Pat. No. 5,739,116; US Pat. No. 5,767,285; US Pat. No. 5,770,701; US ​​Pat. No. 5,770,710; US Pat. No. 5,773,001; US ​​Pat. 5877296; Hinman, LM et al., Cancer Res., 1993, 53, 3336-3342; Lode, HN et al., Cancer Res., 1998, 58, 2925-2928), anthracyclines such as daunomycin or doxorubicin (Kratz, F et al., Curr. Med. Chem., 2006, 13, 477-523; Jeffrey, SC et al., Bioorg. Med. Chem. Lett., 2006, 16, 358-362; Torgov, MY et al., Bioconjug. Chem., 2005, 16 717-721; Nagy, A. et al., Proc. Natl. Acad. Sci. USA, 2000, 97, 829-834; Dubowchik, GM et al., Bioorg. Med. Chem. Lett., 2002, 12, 1529-1532; King, HD et al., J. Med. Chem., 2002, 45, 4336-4343; US 6630579), methotrexate, vindesine, taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel and ortataxel, trichothecene and CC-1065.

[0311] In other embodiments, D can be an enzymatically active toxin or a fragment thereof, including but not limited to diphtheria A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, aleurites fordii proteins, dianthin proteins, phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotonin, saponin inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and enomycin.

[0312] In other embodiments, D may be a radioactive atom. Various radioactive isotopes can be used to produce radioconjugates. For example, At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 , P 32 , Pb 212 When the radioconjugate is used for detection, it may include a radioactive atom for scintigraphic studies, such as Tc 99 or I 123 , or spin labels for magnetic resonance imaging (MRI), such as I 123 ,I 131 、In 111 、F 19 , C 13 、N 15 , O 17 , gadolinium, manganese, or iron.

[0313] In further embodiments, D may include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, prothiosulfan and thiosulfan; aziridines such as benzodopa, carboquinone, metodopa, udopal; ethyleneimines and methylmelamines including triethylamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trishydroxymethylmelamine; acetocins (particularly bratacin and bratacidone); camptothecins (including the synthetic analogue topotecan); bryostatin; canastatin; CC-1065 (including its synthetic analogues, adolesin, kazeresin and bitzeresin); scutellarin (particularly scutellarin 1 and scutellarin 2); 8); Aplysia; Duocarmycin (including synthetic analogs KW-2189 and CBI-TMI); Acanthopanax; Panclastatin; Hemophilin; Spongestatin; Nitrogen mustards, such as chlorambucil, chlornaphthamide, cholephosphamide, estramustine, ifosfamide, mefenamic acid, mefenamic acid hydrochloride, melphalan, nofbichin, phenylacetylene, prednimustine, trofosfamide, uracil mustard; Nitroureas, such as carmustine, chlorzoxazone, fortemustine, lomustine, nimustine, ranimustine; Antibiotics, such as enediyne antibiotics, such as calicheamicin (Nicolaou, KC et al., Agnew Chem. Intl. Ed., 1994, 33, 183-186), dynamin, espamycin and new carcinostatin chromophores and related chromoprotein enediyne antibiotic chromophores, aclarubicin, actinomycin, erythromycin, azaserine, bleomycin, cactinomycin, keratin, camphormycin, carbophilin, chromomycin, dactinomycin, daunorubicin, detomycin, 6L-norleucine, doxorubicin (including morpholinodoxorubicin, cyanomorpholinodoxorubicin, 2-pyridoxine oxazolidinone (doxorubicin and deoxydoxorubicin), epirubicin, edrubicin, idarubicin, marcelomycin, mitomycin, mycophenolic acid, nogamycin, oliveromycin, pepromycin, phenylpropamycin, puromycin, quinamycin, rorubicin, streptomycin, streptozotocin, tuberculin, ubenimex, ginocin, zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs, such as didopterin, pteropterin, trimetazidine Purine analogs, such as fludarabine, 6-mercaptopurine, thiamine purine, thioguanine; pyrimidine analogs, such as acitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, exetabine, floxuridine, 5-FU; androgens, such as catsterone, dromotazone propionate, epistanolol, mepisteine, testosterone lactone; antiadreners, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as furin Acid; acetylacetone; aldehyde phosphamide glycoside; aminolevulinic acid; amsacrine; besetavir; bisantrene; edaxate; deslipamine; demeclocycline; diazinon; ethylenediamine; elixironium acetate; epothilone; glycolic acid; gallium nitrate; hydroxyurea; lentinan; chloranil; maytansines, such as maytansine and ansamitocin; mitoxantrone; mitoxantrone; mopidamole; adenosine nitrate; pentostatin; methamine mustard; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine;. Razoxane; rhizobactin; tetrazofuran; spirogermanium; taurine; triazone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veratrol A, cochineal A, and agmatine); carbamates; periwinkle; dacarbazine; mannitol; dibromomannitol; dibromodulanol; pibroman; cytosine; arabinoside; cyclophosphamide; thiotepa; taxanes, such as paclitaxel and docetaxel Chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; norvanone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor rubitecan (9-nitrocamptothecin or RFS-2000); difluoromethylornithine; retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above substances. Also included in the definition are anti-hormonal agents used to modulate or inhibit the effects of hormones on tumors, such as anti-estrogens, including, for example, tamoxifen, raloxifene, 4-hydroxytamoxifen, tamoxifen, ketoxifen, LY117018, onaproxyprogesterone and Toremifene ; anti-androgen agents such as flutamide, nilutamide, bicalutamide, leuprolide, goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing substances.

[0314] VIII. Antibodies and Targets

[0315] Currently, many therapeutic antibodies targeting cell surface molecules and / or their ligands are known. These antibodies can be used to select and construct tailored specific recognition binding parts in monospecific or multispecific ADCs. For example, blinatumomab / BLINCYTO (CD3 / CD19), Rituxan / MabTHera / rituximab (CD20), H7 / ocrelizumab (CD20), Zevalin / Ibrizumab (CD20), Arzerra / Ovanumab (CD20), HLL2 / epatuzumab, Inotuzomab (CD22), Zenapax / daclizumab, Simulect / basiliximab (CD25), Herceptin / trastuzumab, Pertuzumab (Her2 / ERBB2), Mylotarg / gemtuzumab (CD33), Raptiva / efalizumab (Cd11a), Erbitux / cetuximab (EGFR, epidermal growth factor receptor), IMC-1121B (VEGF receptor 2), Tysabri / natalizumab (α4-subunit of α4β1 and α4β7 integrins), ReoPro / abciximab (gpIIb-gpIIa and αvβ3-integrin), Orthoclone OKT3 / Muromonab-CD3 (CD3), Benlysta / Belimumab (BAFF), Tolerx / Oteliximab (CD3), Soliris / Eculizumab (C5 complement protein), Actemra / Tocilizumab (IL-6R), Panorex / Edelecomab (EpCAM, epithelial cell adhesion molecule), CEA-CAM5 / Labetuzumab (CD66 / CEA, carcinoembryonic antigen), CT-11 (PD-1, programmed death-1 T-cell inhibitory receptor, CD-d279), H224G11 (c-Met receptor), SAR3419 (CD19), IMC-A12 / Cixutumumab (IGF-1R, insulin-like growth factor 1 receptor), MEDI-575 (PDGF-R, platelet-derived growth factor receptor), CP-675, 206 / Tremelimumab (cytotoxic T-lymphocyte antigen 4), RO5323441 (placental growth factor or PGF), HGS1012 / Mapatumumab (TRAIL-R1), SGN-70 (CD70), Vedotin (SGN-35) / Bentuximab (CD30), and ARH460-16-2 (CD44).

[0316] The monospecific or multispecific ADC disclosed in the present invention can be used for the preparation of drugs for treating tumor diseases, cardiovascular diseases, infectious diseases, inflammatory diseases, autoimmune diseases, metabolic (e.g., endocrine) diseases, or nervous system (e.g., neurodegenerative) diseases. Illustrative, non-limiting examples of such diseases are Alzheimer's disease, non-Hodgkin's lymphoma, B-cell acute and chronic lymphatic leukemia, Burkitt's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, acute and chronic myeloid leukemia, T-cell lymphoma and leukemia, multiple myeloma, glioma, Waldenstrom's macroglobulinemia, cancer (e.g., of the oral cavity, gastrointestinal tract, colon, stomach, pulmonary tract, lung, breast, ovary, prostate, uterus, endometrium, cervix, bladder, pancreas, bone, liver, gallbladder, kidney, skin, and testis), melanoma, sarcoma, glioma and skin cancer, acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndrome, bullous nephritis, Herpes, diabetes mellitus, Henoch-Schonlein purpura, poststreptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis, multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangiitis obliterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis / dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis / polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, psoriasis, or fibrosing alveolitis.

[0317] Many cell surface markers and their ligands are currently known. For example, cancer cells have been reported to express at least one of the following cell surface markers and / or ligands, including but not limited to, carbonic anhydrase IX, alpha-fetoprotein, alpha-actinin-4, A3 (antigen specific for A33 antibody), ART-4, B7, Ba-733, BAGE, BrE3-antigen, CA125, CAMEL, CAP-1, CASP-8 / m, CCCL19, CCCL21, CD1, CD1a, CD2, CD3, CD4, CDS, CD8, CD1-1A, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45 、CD46、CD54、CD55、CD59、CD64、CD66a-e、CD67、CD70、CD74、CD79a、CD80、CD83、CD95、CD126、CD133、CD138、CD147、CD154、CDC27、CDK-4 / m、CDKN2A、CXCR4、CXCR7、CXCL12、HIF-1-α、colon-specific antigen-p(CSAp)、CEA(CEACAM5)、CEACAM6、c-met、DAM、EGFR、EGFRvIII、EGP-1、EGP-2、ELF2-M、Ep-CAM、Flt-1、Flt-3、folate receptor、G250 antigen、GAGE、GROB、HLA-DR、HM1.24. Human chorionic gonadotropin (HCG) and its subunits, Her2 / neu, HMGB-1, hypoxia-inducible factor (HIF-1), HSP70-2M, HST-2 or 1a, IGF-1R, IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, insulin-like growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, 1-4, LAG3, Le-Y, LDR / FUT, macrophage migration inhibitory factor (MIF), MAGE, MAGE-3, MART-1, MART-2, NY-ESO-1, TRAG-3, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5, MUM-1 / 2, MUM-3, NCA66, NCA95, NCA90, pancreatic cancer mucin, placental growth factor, p53, PLAGL2, prostatic acid phosphatase, PSA, PRAME, PSMA, P1GF, ILGF, ILGF-1R, I L-6, IL-25, RS5, RANTES, T101, SAGE, 5100, survivin, survivin-2B, TAC, TAG-72, tenascin, TRAIL receptor, TNF-α, Tn-antigen, Thomson-Friedenreich antigen, tumor necrosis antigen, VEGFR, ED-B fibronectin, WT-1, 17-1A-antigen, complement factors C3, C3a, C3b, C5a, C5, angiogenesis markers, bcl-2, bcl-6, Kras, c-MET, oncogene markers and oncogene products (Sensi, M. et al., Clin. Cancer Res., 2006, 12, 5023-5032; Parmiani, G. et al., J. Immunol., 2007, 178, 1975-1979; Castelli, C. et al., Cancer Immunol. Immuno Her., 2005, 54, 187-207). Therefore, antibodies that recognize such specific cell surface receptors or their ligands can be used to specifically and selectively recognize binding moieties in the monospecific or multispecific ADCs of the present invention, thereby targeting and binding to a variety of disease-related cell surface markers or ligands.

[0318] In some embodiments, for the treatment of cancer / tumors, monospecific or multispecific ADCs are used to target tumor-associated antigens (TAAs), such as those reported in Herberman, "Cancer Immunodiagnosis", in FleisHer, ed., "Clinical Biochemistry of Cancer", p. 347 (American Association of Clinical Chemists, 1979), and US 4150149; US 4361544; US 4444744.

[0319] Reports on tumor-associated antigens include Mizukami et al., Nature Med. 2005 11, 992-997; Hatfield et al., Curr. Cancer Drug Targets 2005, 5229-248; Vallbohmer et al., J. Clin. Oncol. 2005, 23, 3536-3544; and Ren et al., Ann. Surg. 2005, 242, 55-63, each of which is incorporated herein by reference regarding identified tumor-associated antigens. When the disease involves lymphoma, leukemia or autoimmune disease, the targeting antigen can be selected from CD4, CD5, CD8, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD54, CD67, CD74, CD79a, CD80, CD126, CD138, CD154, CXCR4, B7, MUC1 or 1a, HM1.24, HLA-DR, tenascin, VEGF, P1GF, ED-B fibronectin, oncogenes, oncogene products (such as c-Met or PLAGL2), CD66a-d, necrosis antigens, IL-2, T101, TAG, IL-6, MIF, TRAID-R1 (DR4) and TRAIL-R2 (DR5).

[0320] Antibodies against the above antigens can be used as binding domains or parts for preparing ADC or BsADC of the present invention. Different BsADCs can be prepared against two different targets.

[0321] Examples of antigen pairs include CD19 / CD3, BCMA / CD3, different combinations of antigens of the Her family (EGFR, HER2, HER3), IL17RA / IL7R, IL-6 / IL-23, IL-1-β / IL-8, IL-6 or IL-6R / IL-21 or IL-21R, ANG2 / VEGF, VEGF / PDGFR-β, vascular endothelial growth factor-(VEGF) receptor 2 / CD3, PSMA / CD3, EPCAM / CD3, a combination of antigens selected from VEGFR-1, VEGFR-2, VEGFR-3, FLT3, c-FMS / CSF1R, R ET, c-Met, EGFR, Her2 / neu, HER3, HER4, IGFR, PDGFR, c-KIT, BCR, integrins and MMPs with water-soluble ligands selected from VEGF, EGF, PIGF, PDGF, HGF, and angiopoietin, ERBB-3 / c-MET, ERBB-2 / c-MET, EGF receptor 1 / CD3, EGFR / HER3, PSCA / CD3, c-Met / CD3, endosialin / CD3, EPCAM / CD3, IGF-1R / CD3, FAPALPHA / CD3, EGFR / IGF-1R, IL 17A / F, EGF receptor 1 / CD3, and CD19 / CD16. Other examples of bispecific ADCs may have (i) a first specificity for a carbohydrate epitope of an antigen selected from Lewis x-, Lewis b- and Lewis y structures, Globo H structures, KH1, Tn-antigen, TF-antigen and carbohydrate structures of mucins, CD44, glycolipids and glycosphingolipids such as Gg3, Gb3, GD3, GD2, Gb5, Gm1, Gm2, and sialyltetraosylceramide, and (ii) a second specificity for an ErbB receptor tyrosine kinase selected from EGFR, HER2, HER3 and HER4. GD2 in combination with a second antigen binding site is associated with an immune cell selected from the group consisting of T-lymphocytes, NK cells, B-lymphocytes, dendritic cells, monocytes, macrophages, neutrophils, mesenchymal stem cells, neural stem cells.

[0322] The methods disclosed in the present invention can be used to link a monospecific or bispecific antibody to another monospecific or bispecific antibody to prepare a multispecific ADC. By using already available monospecific or bispecific therapeutic binding entities, such as those therapeutic antibodies described above, rapid and easy production of desired multispecific binding molecules can be achieved. By combining two or more single therapeutic molecules to simultaneously target and bind to two or more different epitopes, thereby custom-producing multispecific ADCs, additive / synergistic effects compared to single targeted ADCs can be expected.

[0323] In some embodiments, multispecific ADCs of the invention are prepared using antibody pairs that specifically interact with and exhibit measurable affinity for the following target pairs.

[0324]

[0325]

[0326] In some embodiments, BsADC comprises a bispecific single chain antibody, wherein the two binding domains of the bispecific single chain antibody are connected by a linker. In some embodiments, the linker comprises a portion such as cysteine ​​or a non-natural amino acid residue, which can be used for site-specific conjugation of an antibody to a non-immunogenic polymer drug conjugate such as a pegylated drug conjugate. In some other embodiments, one or both of the two binding domains of the bispecific single chain antibody comprises cysteine ​​or a non-natural amino acid residue, which can be used for site-specific conjugation of an antibody to a non-immunogenic polymer drug conjugate such as a pegylated drug conjugate.

[0327] In a preferred embodiment, the BsADC is a conjugate of two antibodies or antigen-binding fragments thereof (eg, Fab, scFv, etc.) that specifically interact with two different epitopes of Her2 and show measurable affinity.

[0328] IX. Synthesis

[0329] Once the polyethylene glycol of the desired size and number of branches is selected, the terminal functional groups of the polyethylene glycol, such as hydroxyl, carboxyl, etc., can be converted into heterobifunctional groups with terminal branches using any method recognized in the art (WO2018075308). Broadly speaking, heterobifunctional polyethylene glycol with terminal branches can be prepared by the following method: activating the terminal hydroxyl or carboxyl of polyethylene glycol with N-hydroxysuccinimide, in the presence of a base such as 4-dimethylaminopyridine (DMAP), pyridine, etc., in the case where the polyethylene glycol terminal is a hydroxyl, using reagents such as di(N-succinimide) carbonate (DSC), triphosgene (triphosgene), etc., or in the case where the polyethylene glycol terminal is a carboxyl, using coupling reagents such as N, N-diisopropylcarbodiimide (DIPC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), etc., to form activated polyethylene glycol.

[0330] Next, in the presence of a base such as diisopropylamine (DIPEA), the activated polyethylene glycol can be reacted with a trifunctional small molecule such as a lysine derivative H-Lys(Boc)-OH to form a heterobifunctional polyethylene glycol PEG-Lys(Boc)-COOH having a terminal branch with a free carboxyl group and a Boc-protected amino group. It will be appreciated by those of ordinary skill that other terminal functional groups of polyethylene glycol such as halides, amino groups, thiol groups, etc. and other trifunctional small molecules containing a terminal branch from -NH 2 、-NHNH 2 , -COOH, -OH, -C(O)X (X=halide), -N=C=O, -SH, anhydride, halide, maleimido, C=C, C≡C, etc. or any combination of three functional groups from the list of their protected forms.

[0331] Removal of Boc by TFA followed by reaction with a maleimide-tagged spacer such as NHS-PEG2-maleimide yields PEG-Lys(Mal)-COOH.

[0332] Alternatively, a cytotoxic drug (e.g., MMAE) linked to a trigger unit (e.g., val-cit) and a self-immolative spacer (e.g., PABC) is coupled to a branching unit via a coupling reagent such as EDC / HOBT to produce a BD:

[0333]

[0334] The target product, i.e., the PEGylated drug conjugate PEG-Lys(Mal)-(Val-Cit-PAB-MMAE), can be formed by coupling PEG-Lys(MAL)-COOH with BD via a coupling agent such as DCC. 2 .

[0335] Monospecific antibodies or bispecific antibodies such as SCAHer2IIxSCAHer2IV that are divalent against antigens can be prepared by genetic manipulation of the expression system. For example, DNA encoding a bispecific scFv can be synthesized and introduced into an expression system (e.g., CHO cells). The target protein is then expressed and purified by chromatography techniques.

[0336] To prepare a PEGylated single-chain ADC or BsADC that is bivalent against an antigen, a PEGylated drug conjugate with a maleimide or DBCO functional group can be site-specifically reacted with a free thiol or azide functional group of a genetically inserted or derived bifunctional antibody such as SCAHer2IVxSCAHer2IV or SCAHer2IIxSCAHer2IV to form PEG-Lys(SCAHer2IVxSCAHer2IV)-(Val-Cit-PAB-MMAE) 2 or PEG-Lys(SCAHer2IIxSCAHer2IV)-(Val-Cit-PAB-MMAE) 2 .

[0337] Pegylated multispecific antibodies can be similarly prepared using multispecific antibodies instead of monospecific or bispecific antibodies.

[0338] In addition to the thiol / maleimide or DBCO / azide site-specific conjugation group pairs listed in the present invention, the ordinary technician will understand that other known site-specific conjugation group pairs, such as trans-cyclooctene / tetrazine pairs; carbonyl / hydrazide; carbonyl / oxime; Suzuki-Miyaura cross-coupling reagent pairs; Sonogashira cross-coupling reagent pairs; Staudinger ligation reaction reagent pairs; Knoevenagel-Intra Michael addition reagent pairs; active amine / acrylate pairs, etc. can be similarly designed and used as alternatives for the same purpose (if necessary). The above list of site-specific conjugation group pairs is illustrative only and is not intended to limit the types of site-specific conjugation group pairs suitable for use herein.

[0339] X. Composition

[0340] The present invention also provides a composition, for example, a pharmaceutical composition, comprising a compound of the present invention co-formulated with a pharmaceutically acceptable carrier. For example, the pharmaceutical composition of the present invention may comprise a compound that binds to two different epitopes of the Her2 receptor (e.g., a bispecific antibody drug conjugate).

[0341] The therapeutic formulations of the present invention can be prepared by mixing a monospecific or multispecific molecular drug conjugate having the desired purity with an optional physiologically acceptable carrier, excipient or stabilizer, which can be in the form of a lyophilized preparation or an aqueous solution. Acceptable carriers, excipients or stabilizers are non-toxic to recipients at the dosages and concentrations used, and include buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 1 0 residues) proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN, Pluronic, or polyethylene glycol.

[0342] The formulation may also contain more than one active compound, preferably compounds that have complementary activities and do not adversely affect each other, as required for the specific indication being treated. For example, the formulation may further contain another antibody or multispecific antibody, a cytotoxic agent, a chemotherapeutic agent or an ADC. These molecules may be appropriately present in combination in amounts effective for the intended purpose.

[0343] The active ingredient can also be encapsulated in microcapsules prepared by, for example, coacervation techniques or interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or macroemulsions, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0344] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include solid hydrophobic polymer semipermeable matrices containing monospecific or multispecific molecules in the form of shaped articles, such as films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides (US3773919), copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, such as Lupron Depot (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-d(-)-3-hydroxybutyric acid. Polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can release molecules for more than 100 days, and some hydrogels release proteins in shorter periods of time. When encapsulated antibodies are retained in the body for a long time, they may denature or aggregate due to exposure to moisture at 37°C, resulting in loss of biological activity and possible changes in immunogenicity. Rational stabilization strategies can be designed depending on the mechanism involved. For example, if the aggregation mechanism is found to be intermolecular SS bond formation via thiodisulfide exchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling water content, using appropriate additives, and developing specific polymer matrix compositions.

[0345] The pharmaceutical compositions of the present invention can be administered in combination with therapy, ie, in combination with other agents. Examples of therapeutic agents that can be used in combination therapy are described in more detail below.

[0346] Preparations for in vivo administration must be sterile. This can be easily achieved by filtering with a sterile filtration membrane. Sterile injectable solutions can be prepared by adding the required amount of active compound to an appropriate solvent, combined with one or more of the above-mentioned ingredients as required, and then sterilized microfiltration. In general, the method for preparing a dispersion is to add the active compound to a sterile carrier containing a basic dispersion medium and other required ingredients listed above. In the case of sterile powders for preparing sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying (lyophilization), which produce a powder of the active ingredient plus any other desired ingredients therein from a previously sterile filtered solution.

[0347] XI. Dosage

[0348] The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will depend on the subject being treated and the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form is generally the amount of the composition that produces a therapeutic effect. Typically, out of 100%, this amount ranges from about 0.01% to about 99% of the active ingredient, preferably from about 0.1% to about 70%, and most preferably from about 1% to about 30% of the active ingredient in combination with a pharmaceutically acceptable carrier.

[0349] The dosage regimen is adjusted to provide the best desired response (e.g., therapeutic response). For example, a single administration may be made, several administrations may be made over a period of time, or the dosage may be proportionally reduced or increased depending on the urgency of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as unit doses for subjects to be treated: each unit contains a predetermined amount of active compound, calculated to produce the desired therapeutic effect together with the desired pharmaceutical carrier. The specifications of the dosage unit forms of the present invention are determined by and are directly dependent on: (a) the unique characteristics of the active compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of combining such active compounds to treat individual sensitivities.

[0350] For administration of the monospecific or multispecific molecular drug conjugates of the present invention, the dosage range is about 0.0001 mg / kg to 100 mg / kg relative to the host body weight, more typically 0.01 mg / kg to 50 mg / kg. For example, the dosage can be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight or 10 mg / kg body weight or within the range of 1-10 mg / kg. Exemplary treatment regimens require daily administration, twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every three months, or once every three to six months. The preferred administration regimen of the monospecific or multispecific drug conjugates of the present invention includes administering the monospecific or multispecific drug conjugates by intravenous administration of 1 mg / kg body weight or 3 mg / kg body weight using one of the following administration regimens: (i) six doses every four weeks, then every three months; (ii) once every three weeks; (iii) 3 mg / kg body weight once, then 1 mg / kg body weight every 3 weeks.

[0351] Alternatively, the monospecific or multispecific drug conjugates can be administered as sustained-release formulations, in which case a lower frequency of administration is required. The dosage and frequency may vary depending on the half-life of the monospecific or multispecific drug conjugate in the patient. In general, human antibodies have the longest half-life, followed by humanized antibodies, chimeric antibodies, and non-human antibodies. The dosage and frequency of administration may vary depending on whether the treatment is preventive or therapeutic. In preventive applications, relatively low doses are administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, it is sometimes necessary to use relatively high doses at relatively short intervals until the progression of the disease is reduced or terminated, preferably until the patient shows partial or complete improvement in the symptoms of the disease. Thereafter, a preventive regimen may be administered to the patient.

[0352] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient. The selected dosage level depends on a variety of pharmacokinetic factors, including the activity of the particular composition of the present invention used, the route of administration, the time of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, condition, general health and past medical history of the patient being treated, and other factors well known in the medical field.

[0353] A "therapeutically effective dose" of the monospecific or multispecific molecules of the invention preferably results in a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease asymptomatic periods, or the prevention of damage or disability caused by disease affliction. For example, for the treatment of tumors, a "therapeutically effective dose" preferably inhibits cell growth or tumor growth or metastasis by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, even more preferably at least about 80%, relative to an untreated subject. The ability of an agent or compound to inhibit tumor growth can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, this property of a composition can be assessed by examining the ability of a compound to inhibit, which inhibition is performed in vitro by assays known to those skilled in the art. A therapeutically effective amount of a therapeutic compound can reduce tumor size, reduce metastasis, or improve symptoms in a subject. One of ordinary skill in the art will be able to determine such an amount based on factors such as the size of the subject, the severity of the subject's symptoms, and the particular composition or route of administration selected.

[0354] XII. Administration

[0355] The compositions of the present invention can be administered by one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired results. Preferred routes of administration for the antibodies of the present invention include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, such as by injection or infusion. The phrase "parenteral administration" as used herein refers to a mode of administration other than enteral and topical administration, usually by injection, including but not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the monospecific or multispecific molecular conjugates of the present invention can be administered by non-parenteral routes, such as topical, epidermal or mucosal routes of administration, such as intranasal, oral, vaginal, rectal, sublingual or topical administration.

[0356] The active compound can be prepared with a carrier that will protect the compound from rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Many methods for preparing such formulations have been patented or are generally known to those skilled in the art. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0357] Therapeutic compositions can be used with medical devices known in the art. For example, therapeutic compositions of the present invention can be used with needleless subcutaneous injection devices, such as devices disclosed in US 5399163, US 5383851, US 5312335, US 5064413, US4941880, US 4790824 and US 459655. Examples of well-known implants and assemblies for the present invention include those described in US 4487603, US 4486194, US 4447233, US 4447224, US 4439196 and US 4475196. These patents are incorporated by reference into the present invention. Many other such implants, delivery systems and assemblies are known to those skilled in the art.

[0358] XIII. Treatment Methods

[0359] On the one hand, the present invention relates to using the above-mentioned monospecific or multispecific molecular drug conjugates to treat subjects in vivo, thereby inhibiting the growth and / or metastasis of cancerous tumors. In one embodiment, the present invention provides a method for inhibiting the growth and / or restriction of tumor cells in a subject, comprising administering to the subject a therapeutically effective amount of a monospecific or multispecific molecular drug conjugate.

[0360] Non-limiting examples of preferred cancers to be treated include chronic or acute leukemias, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphocytic lymphoma, breast cancer, ovarian cancer, melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate cancer), colon cancer, and lung cancer (e.g., non-small cell lung cancer). In addition, the present invention includes refractory or recurrent malignancies, the growth of which can be inhibited by the antibodies of the present invention. Examples of other cancers that can be treated using the methods of the invention include bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including asbestos-induced cancers, and combinations of the described cancers.

[0361] As used herein, the term "subject" is intended to include humans and non-human animals. Non-human animals include all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cattle, horses, chickens, amphibians and reptiles, but mammals are preferred, such as non-human primates, sheep, dogs, cats, cattle and horses. Preferred subjects include human patients who need to enhance immune response. The method is particularly suitable for treating human patients with diseases that can be treated by enhancing immune response.

[0362] The above treatment can also be combined with standard cancer treatment. For example, it can be effectively combined with a chemotherapy regimen. In these cases, the dose of the chemotherapeutic agent administered can be reduced (Mokyr, M. et al., Cancer Res., 1998, 58: 5301-5304).

[0363] Other antibodies for activating host immune reactivity can be used or used together with the multispecific molecular drug conjugates of the present invention. The antibodies include molecules that target the surface of dendritic cells and can activate DC function and antigen presentation. For example, anti-CD40 antibodies can effectively replace T cell helper activity (Ridge, J. et al., Nature, 1998, 393: 474-478), and can be used in combination with the multispecific molecular drug conjugates of the present invention (Ito, N. et al., Immunobiology, 2000, 201, 527-540). Similarly, antibodies targeting T cell co-stimulatory molecules such as CTLA-4 (US5811097), CD28 (Haan, J. et al., Immunol. Lett., 2014, 162, 103-112), OX-40 (Weinberg, A. et al., J. Immunol., 2000, 164, 2160-2169), 4-1BB (Melero, I. et al., Nature Med., 1997, 3, 682-685) and ICOS (Hutloff, A. et al., Nature, 1999, 397, 262-266) or antibodies targeting PD-1 (US8008449) and PD-L1 (US 7943743; US 8168179) can also provide increased levels of T cell activation. In another example, the monospecific or multispecific molecular drug conjugates of the present invention can be used in combination with anti-tumor antibodies, such as RITUXAN (rituximab), Herceptin (trastuzumab), BEXXAR (tositumomab), ZEVALIN (ibritumomab tiuxetan), CAMPATH (alemtuzumab), LYMPHOCIDE (epatuzumab), Avastin (bevacizumab) and TARCEVA (erlotinib), etc.

[0364] Definition of terms

[0365] As used herein, the term "alkyl" refers to a hydrocarbon chain, typically about 1 to 25 atoms in length. Such hydrocarbon chains are preferably, but not necessarily, saturated and may be branched or straight-chain, but straight chains are generally preferred. The term C 1-10 Alkyl groups include those having 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 carbons. 1-25 Alkyl includes all alkyl groups having 1 to 25 carbon atoms. Exemplary alkyl groups include methyl, ethyl, isopropyl, n-butyl, n-pentyl, 2-methyl-1-butyl, 3-pentyl, 3-methyl-3-pentyl, etc. As used herein, "alkyl" includes cycloalkyl when referring to three or more carbon atoms. Unless otherwise indicated, alkyl groups may be substituted or unsubstituted.

[0366] As used herein, the term "functional group" refers to a group that can be used to form a covalent bond between the entity to which it is attached and another entity that usually carries other functional groups under normal organic synthesis conditions. A "bifunctional linker" refers to a linker with two functional groups that forms two bonds with the other part of the conjugate.

[0367] As used herein, the term "derivative" refers to a chemically modified compound having additional structural moieties for the purpose of introducing new functional groups or adjusting the properties of the original compound.

[0368] As used in the present invention, term " blocking group " refers to the part that prevents or blocks the reaction of specific chemical reactive functional group in molecule under certain reaction conditions.Various blocking groups are well-known in the art, for example at TW Greene and GM Wuts, Protecting Groups in Organic Synthesis, 3rd edition, Wiley, New York, 1999, and PJ Kocienski, Protecting Groups, 3rd edition, Thieme Chemistry, 2003, and the document wherein quoted all have description.

[0369] As used herein, the term "PEG" refers to polyethylene glycol. The polyethylene glycol used in the present invention generally comprises -(CH 2 CH 2 O) n -structure. The polyethylene glycol can have a variety of molecular weights, structures or geometries. The polyethylene glycol group may contain end-capping groups that do not readily undergo chemical transformation under typical synthetic reaction conditions. Examples of end-capping groups include -OC 1-25 Alkyl or -Oaryl.

[0370] As used herein, the term "PEGylation" refers to chemical modification with polyethylene glycol.

[0371] As used in the present invention, the term "linker" refers to an atom or a collection of atoms that are used to connect interconnected parts, such as antibodies and polymer molecules. The linker can be cleavable or non-cleavable. The preparation of various linkers for conjugates is described in the literature, including, for example, GoldmacHer et al., Antibody-drug Conjugates and Immunotoxins: From Pre-clinical Development to THErapeutic Applications, Chapter 7, in Linker Technology and Impact of Linker Design on ADC properties, Edited by Phillips GL; Ed. Springer Science and Business Media, New York (2013). Cleavable linkers include groups or parts that can be cleaved under certain biological or chemical conditions. Examples include enzymatically cleaved disulfide bonds, 1,4- or 1,6-benzyl elimination, trimethyl lock systems, self-cleavage systems based on N-diglycine (bicine), acid-labile silyl ether linkers and other photolabile linkers.

[0372] As used herein, the term "linking group" or "linker" refers to a functional group or moiety that connects different parts of a compound or conjugate. Examples of linking groups include, but are not limited to, amides, esters, carbamates, ethers, thioethers, disulfides, hydrazones, oximes and half-carbamates, carbodiimides, acid-labile groups, photolabile groups, peptidase-labile groups, and esterase-labile groups. For example, the linker portion and the polymer portion can be connected to each other via an amide or carbamate linking group.

[0373] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably to describe the arrangement of amino acid residues in a polymer. Peptides, polypeptides or proteins can be composed of the standard 20 naturally occurring amino acids, in addition to rare amino acids and synthetic amino acid analogs. They can be any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).

[0374] A "recombinant" peptide, polypeptide or protein refers to a peptide, polypeptide or protein produced by recombinant DNA technology; that is, produced by a cell transformed with an exogenous DNA construct encoding the desired peptide. A "synthetic" peptide, polypeptide or protein refers to a peptide, polypeptide or protein prepared by chemical synthesis. When used in reference to, for example, a cell, or a nucleic acid, protein or vector, the term "recombinant" means that the cell, nucleic acid, protein or vector has been modified by the introduction of a heterologous nucleic acid or protein or a change in a natural nucleic acid or protein, or that the cell is derived from a cell so modified. Fusion proteins containing one or more of the above sequences and a heterologous sequence are included within the scope of the present invention. A heterologous polypeptide, nucleic acid or gene is derived from a foreign species, or, if from the same species, is substantially modified from its original form. If two fusion domains or sequences are not adjacent to each other in a naturally occurring protein or nucleic acid, they are heterologous to each other.

[0375] "Isolated" peptide, polypeptide or protein refers to a peptide, polypeptide or protein that has been separated from other proteins, lipids and nucleic acids that are naturally associated with it. Polypeptide / protein can constitute at least 10% (that is, any percentage between 10% and 100%, such as 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% and 99%) of the purified preparation dry weight. Purity can be measured by any appropriate standard method, such as by column chromatography, polyacrylamide gel electrophoresis or HPLC analysis. The isolated polypeptide / protein described in the present invention can be purified from natural sources, produced by recombinant DNA technology or by chemical methods.

[0376] "Antigen" refers to a substance that elicits an immune response or binds to a product of such a response. The term "epitope" refers to the region of an antigen to which an antibody or T cell binds.

[0377] As used herein, the term "antibody" includes whole antibodies and any antigen-binding fragments or single chains thereof. Whole antibodies are glycoproteins that contain two heavy (H) chains and two light (L) chains linked at least by disulfide bonds. Each heavy chain includes a heavy chain variable region (V H ) and the heavy chain constant region. The heavy chain constant region consists of three domains: C H 1, C H 2 and C H 3. Each light chain includes a light chain variable region (V L ) and the light chain constant region (C L ), the light chain constant region includes one domain. V H and V L The V region can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V LIt consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy chain variable region CDR and FR are HFR1, HCDR1, HFR2, HCDR2, HFR3, HCDR3, HFR4. The light chain variable region CDR and FR are LFR1, LCDR1, LFR2, LCDR2, LFR3, LCDR3, LFR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (such as effector cells) and the first component (CIq) of the classical complement system.

[0378] As used herein, "antibody fragments" may comprise a portion of an intact antibody, typically including the antigen binding region and / or variable region of an intact antibody and / or an Fc region of an antibody that retains FcR binding ability. Examples of antibody fragments include linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0379] As used herein, an "antigen-binding fragment or portion" of an antibody (or simply "antibody fragment or portion") refers to one or more antibody fragments that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment or portion" of an antibody include: (i) a Fab fragment, which is composed of V L , V H , C L and C H I domain composed of monovalent fragments; (ii) F (ab ') 2 (iii) a Fab′ fragment, which is essentially a Fab with part of the hinge region; (iv) a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (v) a Fab′ fragment, which is essentially a Fab with part of the hinge region; H and C H I domain; (v) the Fd fragment consisting of the V domain of a single antibody arm; L (vi) dAb, which is composed of a VH domain; (vii) a single complementarity determining region (CDR); and (viii) a nanobody, which is a heavy chain variable region comprising one variable domain and two constant domains. In addition, although the two domains V L and V H Encoded by separate genes, they can be joined using recombinant methods via synthetic linkers that enable them to become V L and V HThe present invention relates to a protein single chain that is paired with a region to form a monovalent molecule (called a single-chain Fv (scFv)); see, for example, Bird et al., Science 1988, 242, 423-426; and Huston et al., Proc. Natl. Acad. Sci. USA 1988, 85, 5879-5883. Such single-chain antibodies are also intended to be included in the term "antigen-binding fragment or portion" of an antibody. These antibody fragments are obtained using conventional techniques known to those skilled in the art and are screened and used in the same manner as intact antibodies.

[0380] As used herein, the term "Fc fragment" or "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain.

[0381] The term "monoclonal antibody" as used in the present invention refers to an antibody obtained from a population of basic homologous antibodies, i.e., the single antibodies constituting the population are identical except for the naturally occurring mutations that may be present in a small amount. Monoclonal antibodies have a high degree of specificity, directed against a single antigenic site. In addition, in contrast to conventional (polyclonal) antibody preparations that generally include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on an antigen. The modifier "monoclonal" indicates the characteristics of an antibody obtained from a population of basic homologous antibodies, and is not interpreted as requiring the antibody to be produced by any specific method. For example, the monoclonal antibody used in the present invention can be prepared by the hybridoma method first described by Kohler and Milstein (Kohler, G. et al., Nature, 1975, 256, 495-497), which is incorporated by reference into the present invention, or can be prepared by a recombinant DNA method (US 4816567), which is incorporated by reference into the present invention. Monoclonal antibodies can also be isolated from phage antibody libraries by using the techniques described in, for example, Clackson et al., Nature, 1991, 352, 624-628, and Marks et al., J Mol Biol, 1991, 222, 581-597, each of which is incorporated herein by reference.

[0382] The monoclonal antibodies of the present invention specifically include "chimeric" antibodies in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, and fragments of these antibodies, as long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; Morrison et al., Proc Natl Acad Sci USA, 1984, 81, 6851-6855; Neuberger et al., Nature, 312, 1984, 604-608; Takeda et al., Nature, 1985, 314, 452-454; International Patent Application No. PCT / GB85 / 00392, each of which is incorporated herein by reference).

[0383] The "humanized" form of non-human (e.g., mouse) antibodies is a chimeric antibody comprising the minimum sequence derived from non-human immunoglobulin. For the vast majority, humanized antibodies are human immunoglobulins (receptor antibodies), wherein the residues from the hypervariable regions of receptors are replaced by the residues from the hypervariable regions with desired specificity, affinity, and ability from non-human species (donor antibodies), such as mice, rats, rabbits, or non-human primates. In some cases, the Fv framework region (FR) residues of human immunoglobulin are replaced by corresponding non-human residues. In addition, humanized antibodies may include residues that do not occur in receptor antibodies or donor antibodies. These modifications are carried out to further optimize the performance of antibodies. Typically, humanized antibodies include at least one and typically two variable domains substantially all, wherein all or substantially all of the hypervariable loops correspond to those hypervariable loops of non-human immunoglobulins, and all or substantially all of the FR residues are those residues of human immunoglobulin sequences. Optionally, humanized antibodies also include at least a portion of an immunoglobulin constant region (Fc), typically a constant region (Fc) of a human immunoglobulin. Further details may be found in Jones et al., Nature, 1986, 321, 522-525; Riechmann et al., Nature, 1988, 332, 323-329; Presta, Curr Op Struct Biol, 1992, 2, 593-596; U.S. Pat. No. 5,225,539, each of which is incorporated herein by reference.

[0384] A "human antibody" refers to any antibody having a completely human sequence, such as can be obtained from a human hybridoma, a human phage display library, or a transgenic mouse expressing human antibody sequences.

[0385] The term "pharmaceutical composition" refers to the combination of an active agent with an inert or active carrier, making the composition particularly suitable for diagnostic or therapeutic use, either in vivo or ex vivo.

[0386] As used herein, "pharmaceutically acceptable carriers" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. that are physiologically compatible. "Pharmaceutically acceptable carriers" do not cause undesirable physiological effects after being administered to a subject or administered to a subject. The carrier in the pharmaceutical composition must be "acceptable", which also means that it is compatible with the active ingredient and can stabilize it. One or more solubilizing agents can be used as a pharmaceutical carrier to deliver the active agent. Examples of pharmaceutically acceptable carriers include, but are not limited to, biocompatible carriers, adjuvants, additives, and diluents to obtain compositions that can be used as dosage forms. Examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, and sodium lauryl sulfate. Remington's Pharmaceutical Sciences describes other suitable pharmaceutical carriers and diluents, as well as the pharmaceutical necessities they use. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). The therapeutic compound may include one or more pharmaceutically acceptable salts. "Pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the parent compound and do not impart any undesired toxicological effects (see, eg, Berge, SM et al., J. Pharm. Sci. 1997, 66: 1-19).

[0387] As used herein, "treatment" or "treating" refers to the administration of a compound or agent to a subject suffering from a disease or at risk of developing a disease, with the intent to cure, alleviate, relieve, remedy, delay the onset of, prevent or ameliorate the disease, a symptom of the disease, a condition secondary to the disease, or a susceptibility to the disease.

[0388] An "effective amount" refers to the amount of active compound / agent required to impart a therapeutic effect to a subject. As will be appreciated by those skilled in the art, effective doses will vary depending on the type of condition being treated, the route of administration, the use of excipients, and the possibility of co-use with other therapeutic treatments. A therapeutically effective amount of a combination for treating a neoplastic condition is one that will result in, for example, a decrease in tumor size, a decrease in the number of tumor foci, or a decrease in tumor growth compared to an untreated animal.

[0389] As disclosed in the present invention, some numerical ranges are provided. It should be understood that, unless the context clearly specifies otherwise, each intermediate value between the upper and lower limits of the range is also specifically disclosed, to one tenth of the lower limit unit. Each smaller range between any specified value or intermediate value in the range and any other statement or intermediate value in the range is included in the present invention. The upper and lower limits of these smaller ranges can be independently included in the range or excluded from the range, and each range including any one, zero or two restrictions in a smaller range is also included in the present invention, subject to any special exclusion of restrictions in the specified range. In the case where the range includes one or two restrictions, the scope excluding one or both of those included restrictions is also included in the present invention.

[0390] The term "about" generally refers to plus or minus 10% of the number shown. For example, "about 10%" can mean a range of 9% to 11%, while "about 1" can mean 0.9 to 1.1. Other meanings of "about" such as rounding are apparent from the context, so, for example, "about 1" can also mean from 0.5 to 1.4. Example

[0391] The following examples are helpful for further understanding of the present invention, but are not intended to limit the effective scope of the present invention in any way.

[0392] Example 1: 30 km PEG-Lys(Mal)-(Val-Cit-PAB-MMAE) 4 Preparation

[0393] Preparation of branched linker intermediate compound 7 ( Figure 1 )

[0394] Under argon at room temperature, 1 (3.1 g, 10 mmol) was added to dry CH 2 Cl 2 2 (2.6 g, 12 mmol, 1.2 eq.), EDCI (2.87 g, 15 mmol, 1.5 eq.) and HOBt (0.27 g, 2 mmol, 0.2 eq.) were added to a 50 mL solution. The mixture was stirred until complete conversion was observed by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted and the organic layer was washed with brine and then with Na 2 SO 4 Dry, filter and concentrate in vacuo.The crude reaction mixture is purified by chromatography on silica gel to afford the product 3.

[0395] To a solution of 3 (2.6 g, 5 mmol) in THF (50 mL) was added 1 M LiOH (20 mL, 20 mmol, 4.0 equiv) under argon at room temperature. The mixture was stirred until complete conversion was observed by TLC. After the reaction was complete, the mixture was washed with CH 2 Cl 2 The mixture was extracted and the organic layer was washed with brine and then with Na 2 SO 4 Dry, filter and concentrate in vacuo.The crude reaction mixture is purified by chromatography on silica gel to give the product 4.

[0396] 4 (2.3 g, 5 mmol) was added to dry CH 2 Cl 2 5 (1.6 g, 6 mmol, 1.2 eq.), EDCI (1.4 g, 7.5 mmol, 1.5 eq.) and HOBt (0.14 g, 1 mmol, 0.2 eq.) were added to a 50 mL solution. The mixture was stirred until complete conversion was observed by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted and the organic layer was washed with brine and then with Na 2 SO 4 Dry, filter and concentrate in vacuo.The crude reaction mixture is purified by chromatography on silica gel to give the product 6.

[0397] Diethylamine (1.0 mL) was added to a solution of 6 (0.97 g, 1.0 mmol) in DMF (10 mL) and the reaction was carried out at room temperature for 1.5 hours. Diethylamine and solvent were removed in vacuo at a bath temperature not exceeding 30° C. The residue was triturated with ether (25 mL). The precipitated solid was collected, filtered, washed twice with ether (2×20 mL) and dried in vacuo to give product 7.

[0398] Preparation of compound 14 Val-Cit-PAB-MMAE ( Figure 2 )

[0399] Fmoc-Val-OH 8 (3.4 g, 10 mmol, 1.0 eq.) and N-hydroxysuccinimide (1.5 g, 13 mmol, 1.3 eq.) were dissolved in CH 2 Cl 2(60mL) and THF (20mL) in a mixture, and EDCI (2.5g, 13mmol, 1.3 equivalents) was added to the above solution. The solution was then slowly warmed to room temperature. The reaction mixture was stirred at room temperature until the reaction was complete. The reaction mixture was then concentrated under reduced pressure. The concentrated residue was dissolved in THF and filtered to remove EDU. The filtrate was concentrated and re-slurried with n-heptane at 5-10°C for 12 hours. The solid was filtered, washed and dried under vacuum to obtain Fmoc-Val-OSu.

[0400] Fmoc-Val-OSu (4.4 g, 10 mmol, 1.0 eq) was dissolved in acetonitrile (50 mL) at room temperature, and then a solution of sodium carbonate (1.2 g, 11 mmol, 1.1 eq) and L-citrulline (1.9 g, 11 mmol, 1.1 eq) in water (50 mL) was added. The reaction mixture was stirred at 35 °C for several hours until the reaction was complete. The mixture was cooled to 20 °C, quenched with 15% citric acid (150 mL), and washed with EtOAc / i -PrOH (9:1) (200 mL x 2) extraction. The combined organic phase was washed with water (140 mL) and then with anhydrous Na 2 SO 4 After drying and concentration, the residue was washed with methyl tert-butyl ether to give Fmoc-Val-Cit-OH 9.

[0401] Fmoc-Val-Cit-OH 9 (3.0 g, 6.0 mmol, 1.0 equiv) and 4-aminobenzyl alcohol (1.5 g, 12.1 mmol, 2.0 equiv) were dissolved in CH 2 Cl 2 (70 mL) and MeOH (30 mL). EEDQ (3.0 g, 12.1 mmol, 2.0 eq) was added and the solution was stirred at room temperature for 1 day. Additional EEDQ (1.5 g, 6.0 mmol, 1.0 eq) was added and the solution was stirred for 12 hours. The reaction mixture was concentrated and the residue was washed with methyl tert-butyl ether to give Fmoc-Val-Cit-PAB-OH 10.

[0402] To a solution of Fmoc-Val-Cit-PAB-OH 10 (2.0 g, 3.3 mmol, 1.0 eq.) in DMF (20 mL) was added p-nitrobenzoyl chloride 11 (1.2 g, 6.6 mmol, 2.0 eq.) and pyridine (0.4 mL, 5.0 mmol, 1.5 eq.). The reaction mixture was stirred at room temperature for 12 h and concentrated. The residue was washed with EtOAc / methyl tert-butyl ether to give product 12.

[0403] To a solution of 12 (1.3 g, 1.7 mmol, 1.0 eq) in DMF (3.4 mL) was added HOBt (376 mg, 2.78 mmL, 1.6 eq) and pyridine (0.85 ml) at room temperature, followed by MMAE (1.0 g, 1.39 mmol). The solution was stirred at room temperature for 24 hours. The reaction mixture was concentrated and the residue was purified by chromatography on silica gel to give the product Fmoc-Val-Cit-PAB-MMAE13.

[0404] To a solution of Fmoc-Val-Cit-PAB-MMAE 13 (1.4 g, 1.1 mmol) in DMF (20 mL) was added Et 2 NH (5 mL), the solution was stirred at room temperature for 12 hours. The reaction mixture was concentrated and the residue was washed with EtOAc / methyl tert-butyl ether to give the product 14.

[0405] Compound 19 30k mPEG-Lys(Mal)-(MMAE) 4 Preparation ( Figure 3 )

[0406] H-Lys(boc)-OH (369 mg, 1.5 mmol, 3.0 eq) was added to 100 mL of anhydrous DMF, followed by DIEA (5.0 mmol, 10.0 eq), compound 15 (15 g, 0.5 mmol, 1.0 eq) and 150 mL of anhydrous CH 2 Cl 2 The mixture was stirred at room temperature overnight under argon. The insoluble material was filtered off. The solvent was removed and the residue was purified by centrifugation from CH 2 Cl 2 The isolated solid was recrystallized from ACN / 2-propanol again. The product was dried under vacuum at 40°C for 4 hours to obtain product 16.

[0407] Under argon at room temperature, 16 (15 g, 0.5 mmol) was added to dry CH 2 Cl 2 7 (1.1 g, 1.5 mmol, 3.0 equiv.), EDCI (0.58 g, 3.0 mmol, 6.0 equiv.) and HOBt (0.61 g, 4.5 mmol, 9.0 equiv.) were added to the solution (150 mL). The mixture was stirred at room temperature overnight under argon. The solvent was removed and the residue was purified by distillation from CH 2 Cl 2 The precipitated solid was recrystallized from ACN / 2-propanol again. The product was dried under vacuum at 40°C for 4 hours to obtain product 17.

[0408] 17 (9.0 g, 0.3 mmol) was dissolved in CH 2 Cl 2 (90 mL), then TFA (45 mL) was added. The mixture was stirred at room temperature for 1 hour. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by 2 Cl 2 / methyl tert-butyl ether and recrystallized twice. The product was dried under vacuum at 40°C to generate an intermediate. The dried intermediate (6.0 g, 0.2 mmol, 1.0 equiv) was then dissolved in anhydrous CH 2 Cl 2 The solution was cooled to 0-5°C, and DIPEA (517 mg, 4 mmol, 20 equivalents) and NHS-PEG were added at 0-5°C. 2 -Mal (0.22 g, 0.5 mmol, 2.5 equiv.). The mixture was stirred at 0-5°C for 2 hours, then allowed to slowly warm to room temperature and kept at room temperature overnight under argon. After the reaction, the solvent was removed and the residue was purified by centrifugation from CH 2 Cl 2 The precipitated solid was recrystallized from ACN / 2-propanol again. The isolated product was dried under vacuum at 40°C for 4 hours to obtain product 18.

[0409] Under argon at room temperature, 18 (3.0 g, 0.1 mmol) was added to dry CH 2 Cl 2 14 (0.9 g, 0.8 mmol, 8.0 equiv), EDCI (0.46 g, 2.4 mmol, 24 equiv) and HOBt (0.49 g, 3.6 mmol, 36 equiv) were added to a 30 mL solution. The mixture was stirred at room temperature overnight under argon. The solvent was removed and the residue was purified by evaporation from CH 2 Cl 2 The precipitated solid was recrystallized from ACN / 2-propanol again. The isolated product was dried under vacuum at 40°C for 4 hours to obtain product 19.

[0410] Example 2: Preparation of SCAHer2xSCAHer2

[0411] The bispecific single-chain antibody (SCA) fragments of anti-Her2 (SCAHer2)-1 and anti-Her2 (SCAHer2)-2 can be expressed in mammalian cells (e.g., using EasySelect TMThe SCAHer2-1xSCAH2-2 was prepared by recombinant DNA technology in CHO (e.g., CHO) or yeast (e.g., Pichia pastoris expression kit containing pPICZ vector). The DNA sequence of SCAHer2-1xSCAH2-2 corresponding to the following (SEQ ID NO: 1) amino acid sequence was synthesized and cloned into an expression vector and transformed into a host cell. The expressed protein was purified by Ni chelating resin or protein L resin. To facilitate subsequent conjugation, a site-specific conjugation functional group thiol was inserted into the linker between the two Her2 SCAs by recombinant DNA technology.

[0412] Amino acid sequence of SCAHer2IIxSCAHer2IV (SEQ ID NO: 1):

[0413]

[0414]

[0415] Example 3: 30 km PEG-(SCAHer2xSCAHer2)-(Val-Cit-PAB-MMAE) 4 Preparation ( Figure 4 )

[0416] The protein SCAHer2 / SCAHer2 was treated with a PBS buffer (pH = 7.4) using the reducing agent TCEP-HCl for 30 minutes at room temperature, and then the pH was adjusted to pH 6.8 using a stock solution of 500 mM sodium phosphate at pH = 4.12. The treated protein was concentrated to 5 mg / mL before PEGylation. 5 to 10 molar equivalents of compound 19 [30 kmPEG-Lys(Mal)-(Val-Cit-PAB-MMAE) 4 ] at room temperature for 3 hours. The reaction was quenched with 10 mM L-cystine at room temperature for 10 minutes. The final product PEG-Lys(SCAHer2 / SCAHer2)-(Val-Cit-PAB-MMAE) 4 Purification was performed using a cation exchange chromatography column (CM Fast Flow) in 20 mM phosphate buffer at pH 6.5. Target compound 20 was confirmed by SEC-HPLC and cell-based activity assays.

[0417] Example 4: Preparation of Val-Cit-PABC-MMAE ( Figure 5 )

[0418] Fmoc-Val-OSu (Compound 2): Fmoc-Val-OH (20.3 g, 60.0 mmol) and N-hydroxysuccinimide (9.0 g, 78.0 mmol) were dissolved in CH 2 Cl 2 (120 mL) and THF (40 mL). Separately, EDCI (13.8 g, 72.0 mmol) was dissolved in CH 2 Cl 2 (200 mL), and the solution was cooled to 0-5°C. The Fmoc-Val-OH / NHS solution was then added to the EDCI solution, and the reaction mixture was subsequently warmed to room temperature. The reaction mixture was stirred at room temperature until the reaction was complete. The reaction mixture was then concentrated under reduced pressure as much as possible, and the residue was purified by CH 2 Cl 2 The concentrated residue was dissolved in THF (800 mL) and filtered to remove EDU. The filtrate was concentrated under reduced pressure and the residue was slurried with n-heptane (800 mL) at 5-10°C for 12 hours. The solid was filtered, washed and dried in vacuo to give Fmoc-Val-OSu (2) (23.8 g, 91%) as a white powder. HRMS (ESI) was used for C 24 H 24 N 2 O 6 Na[M+Na] + The calculated value is 459.1532 and the measured value is 459.1523.

[0419] Fmoc-Val-Cit (Compound 3): Fmoc-Val-Osu (9.8 g, 22.5 mmol) was dissolved in DME (150 mL) at room temperature. Separately, sodium bicarbonate (2.1 g, 24.7 mmol) was dissolved in water (150 mL) at room temperature, and then L-citrulline (4.3 g, 24.7 mmol) was added to obtain a uniform clear solution. The prepared L-citrulline solution was then added to the Fmoc-Val-Osu solution. THF (75 mL) was added, and the reaction mixture was stirred at room temperature for 16 hours until the reaction was complete. The reaction mixture was acidified with 15% citric acid (200 mL) and concentrated using a rotary evaporator (Rotavapor). The residue was suspended in water (500 mL) for 2 hours, then filtered and dried in vacuo. The dried solid was resuspended in methyl tert-butyl ether (500 mL), stirred for 12 hours, filtered, washed and dried in vacuo to obtain Fmoc-Val-Cit (3) (6.8 g, 61%) as a white powder. HRMS (ESI) was used for C 26 H 33 N 4O 6 [M+H] + The calculated value is 497.2400 and the measured value is 497.2388.

[0420] Fmoc-Val-Cit-PABOH (Compound 4): EEDQ (4.95 g, 20.0 mmol) was added to a CH 2 Cl 2 (350mL) and MeOH (150mL) solution. The reaction mixture was stirred at room temperature for 24 hours. Additional EEDQ (2.5 g, 10.0 mmol) was added to the reaction, and the mixture was stirred for another 24 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the resulting residue was slurried in methyl tert-butyl ether (800 mL) for 12 hours. The solid was filtered, washed and dried in vacuo to give compound 4 (4.1 g, 69%) as a white powder. HRMS (ESI) was used for C 33 H 40 N 5 O 6 [M+H] + The calculated value is 602.2979 and the measured value is 602.2969.

[0421] Fmoc-Val-Cit-PABC-PNP (Compound 5): DIPEA (2.5 mL, 15.0 mmol) was added to a DMF (52 mL) solution of compound 4 (5.2 g, 8.6 mmol) and bis(4-nitrophenyl) carbonate (4.9 g, 16.1 mmol) at room temperature. The reaction mixture was stirred at room temperature for 5 hours until the reaction was completed. The product was precipitated by adding anhydrous ethyl acetate (250 mL) and methyl tert-butyl ether (250 mL). The suspension was cooled to 0 ° C and stirred for 30 minutes. The solid was separated by filtration, washed and dried in vacuo to give Fmoc-Val-Cit-PABC-PNP (5) (4.7 g, 72%) as a light yellow powder. HRMS (ESI) was used for C 40 H 43 N 6 O 10 [M+H] + The calculated value is 767.3041 and the measured value is 767.3045.

[0422] Fmoc-Val-Cit-PABC-MMAE (Compound 6): Compound MMAE (2.0 g, 1.8 mmol) and Fmoc-Val-Cit-PABC-PNP (5) (2.8 g, 3.6 mmol) were dissolved in DMF (20 mL). HOBt (0.75 g, 5.6 mmol) and pyridine (1.7 mL) were then added, and the reaction mixture was stirred at room temperature for 24 hours. After the reaction was completed, the reaction mixture was cooled to 0 ° C, and methyl tert-butyl ether (180 mL) was then added to precipitate the product. The slurry was stirred for 3-5 hours and filtered, washed and dried under vacuum. The crude product was purified by column purification to give Fmoc-Val-Cit-PABC-MMAE (6) (3.0 g, 80%) as a yellow powder. HRMS (ESI) was used for C 73 H 105 N 10 O 14 [M+H] + The calculated value is 1345.7812 and the measured value is 1345.7820.

[0423] Val-Cit-PABC-MMAE (Compound 7): Compound 6 (3.0 g, 2.2 mmol) was suspended in anhydrous DMF (40 mL) and stirred at room temperature until a uniform suspension was formed. Diethylamine (10 mL) was then added and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, methyl tert-butyl ether (100 mL) and ethyl acetate (50 mL) were added within 60 minutes. The resulting mixture was stirred at 0°C for 4 hours. The solid was filtered and dried in vacuo to give Val-Cit-PABC-MMAE (7) (2.3 g, 92%) as a light yellow powder. HRMS (ESI) was used for C 58 H 95 N 10 O 12 [M+H] + The calculated value is 1123.7131 and the measured value is 1123.7142.

[0424] Example 5: Preparation of Compound 13 (Branched Linker B with 2XMMAE) ( Figure 6 )

[0425] Compound 10: Compound 8 (0.62 g, 2.0 mmol) was added to dry CH 2 Cl 23,3′-azadiyldipropionic acid di-tert-butyl ester (9) (0.62 mL, 2.2 mmol), EDCI (0.58 g, 3.0 mmol) and HOBt (54 mg, 0.4 mmol) were added to the (15 mL) solution. The reaction mixture was stirred at room temperature and monitored by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted with (30 mL x 2), the organic layers were combined, washed with brine (20 mL) and washed with Na 2 SO 4 The solution was concentrated using a rotary evaporator. The crude reaction mixture was purified by chromatography on silica gel to afford the product 10 (1.1 g, 96%) as a colorless oil. HRMS (ESI) was used for C 32 H 43 N 2 O 7 [M+H] + The calculated value is 567.3070 and the measured value is 567.3062.

[0426] Compound 11: Compound 10 (5.2 g, 9.2 mmol) was dissolved in CH 2 Cl 2 (100 mL), then TFA (25 mL) was added. The mixture was stirred at room temperature for 3 hours. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by chromatography on silica gel to give the product 11 (3.4 g, 83%) as a colorless oil. HRMS (ESI) for C 24 H 27 N 2 O 7 [M+H] + The calculated value is 455.1818 and the measured value is 455.1824.

[0427] Compound 12: Under argon at room temperature, compound 11 (41 mg, 0.091 mmol) was added to dry CH 2 Cl 2 To a stirred solution of 4-nitropropene (2 mL) and DMF (2 mL) was added Val-Cit-PABC-MMAE (7) (224 mg, 0.2 mmol), EDCI (52 mg, 0.27 mmol) and HOBt (5 mg, 0.04 mmol). The reaction mixture was stirred at room temperature and monitored by TLC. After completion of the reaction, the mixture was concentrated in vacuo. The residue was purified by HPLC using a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 12 (74 mg, 31%) as a light yellow solid. HRMS (ESI) was used for C 140 H212 N 22 O 29 [M+2H] 2+ The calculated value is 1333.2912 and the measured value is 1333.2907.

[0428] Compound 13: Diethylamine (0.6 mL) was added to a solution of compound 12 (73 mg) in DMF (3 mL). The reaction was allowed to proceed at room temperature for 4 hours. The reaction mixture was concentrated using a rotary evaporator and the residue was purified using HPLC with a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 13 (71 mg, 99%) as a light yellow solid. HRMS (ESI) was used for C 125 H 202 N 22 O 27 [M+H] + The calculated value is 1222.2572 and the measured value is 1222.2560.

[0429] Example 6: Preparation of Compound 18 (Branched Linker B with 2XMMAE) ( Figure 7 )

[0430] Compound 15: Compound 14 (0.68 g, 2.0 mmol) was added to dry CH 2 Cl 2 3,3′-Azadiyldipropionic acid di-tert-butyl ester (9) (0.64 mL, 2.2 mmol), EDCI (0.58 g, 3.0 mmol) and HOBt (54 mg, 0.4 mmol) were added to the (10 mL) solution. The reaction mixture was stirred at room temperature and monitored by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted with 4% paraformaldehyde (2×30 mL), and the combined organic layers were washed with brine (20 mL) and diluted with Na 2 SO 4 The residue was purified by chromatography on silica gel to give the product 15 (1.2 g, 99%) as a colorless oil. HRMS (ESI) was used for C 34 H 47 N 2 O 7 [M+H] + The calculated value is 595.3383 and the measured value is 595.3380.

[0431] Compound 16: Compound 15 (0.5 g, 0.84 mmol) was dissolved in CH 2 Cl2 (6.0 mL), then TFA (3.0 mL) was added. The mixture was stirred at room temperature for 3 hours. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by chromatography on silica gel to give the product 16 (0.34 g, 85%) as a colorless oil. HRMS (ESI) for C 26 H 31 N 2 O 7 [M+H] + The calculated value is 483.2131 and the measured value is 483.2127.

[0432] Compound 17: Compound 16 (185 mg, 0.383 mmol) was added to dry CH 2 Cl 2 To a mixture of 4-nitropropene (8 mL) and DMF (8 mL) was added Val-Cit-PABC-MMAE (7) (947 mg, 0.843 mmol), EDCI (238 mg, 1.23 mmol) and HOBt (26 mg, 0.19 mmol). The reaction mixture was stirred at room temperature and monitored by HPLC. After the reaction was completed, the mixture was concentrated using a rotary evaporator. The residue was purified by HPLC using a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 17 (0.56 g, 54%) as a light yellow solid. HRMS (ESI) was used for C 142 H 216 N 22 Q 29 [M+H] + The calculated value is 2694.6137 and the measured value is 2694.6146.

[0433] Compound 18: Diethylamine (2 mL) was added to a solution of compound 17 (0.62 g) in DMF (5 mL). The reaction mixture was allowed to stand at room temperature for 2 hours. The reaction mixture was concentrated using a rotary evaporator and the residue was purified using HPLC with a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 18 (0.51 g, 89%) as a light yellow solid. HRMS (ESI) was used for C 127 H 205 N 22 O 27 [M+H] + The calculated value is 2471.5378, and the measured value is 2471.5369; 127 H 206 N 22 O27 [M+2H] 2+ The calculated value is 1236.2728 and the measured value is 1236.2744.

[0434] Example 7: Preparation of Compound 22 (Branched Linker B with 4XMMAE) ( Figure 8 )

[0435] Compound 20: Compound 19 (0.76 g, 2.0 mmol) was added to dry CH 2 Cl 2 3,3′-Azadiyldipropionic acid di-tert-butyl ester (9) (0.64 mL, 2.2 mmol), EDCI (0.58 g, 3.0 mmol) and HOBt (54 mg, 0.4 mmol) were added to the (10 mL) solution. The reaction mixture was stirred at room temperature and monitored by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted with 4% paraformaldehyde (2×30 mL), and the combined organic layers were washed with brine (20 mL) and diluted with Na 2 SO 4 The crude reaction mixture was purified by chromatography on silica gel to give the product 20 (1.2 g, 99%) as a colorless oil. HRMS (ESI) was used for C 29 H 55 N 4 O 11 [M+H] + The calculated value is 635.3867 and the measured value is 635.3860.

[0436] Compound 21: Compound 20 (0.3 g, 0.47 mmol) was dissolved in CH 2 Cl 2 (4.0 mL), then TFA (2.0 mL) was added. The mixture was stirred at room temperature for 3 hours. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by chromatography on silica gel to give the product 21 (0.34 g, 85%) as a colorless oil. HRMS (ESI) for C 21 H 39 N 4 O 11 [M+H] + The calculated value is 523.2615 and the measured value is 523.2607.

[0437] Compound 22: Compound 21 (39 mg, 0.076 mmol) was added to dry CH 2 Cl 2Compound 18 (0.41 g, 0.17 mmol), EDCI (43 mg, 0.23 mmol) and HOBt (4.0 mg, 0.03 mmol) were added to a stirred solution of a mixture of 4-nitropropene (2 mL) and DMF (2 mL). The reaction mixture was stirred at room temperature and monitored by HPLC. After the reaction was completed, the mixture was concentrated using a rotary evaporator. The residue was purified by HPLC using a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 22 (81 mg, 20%) as a light yellow solid. HRMS (ESI) was used for C 275 H 445 N 48 O 63 [M+3H] 3+ The calculated value is 1810.1053, and the measured value is 1810.1061. 275 H 446 N 48 O 63 [M+4H] 4+ The calculated value is 1357.8310 and the measured value is 1357.8346.

[0438] Example 8: Preparation of Compound 27 (Branched Linker B with 4XMMAE) ( Fig. 9 )

[0439] Compound 24: Compound 21 (0.57 g, 1.1 mmol) was added to dry CH 2 Cl 2 Compound 23 (0.51 g, 2.4 mmol), EDCI (0.67 g, 3.5 mmol), HOBt (74 mg, 0.55 mmol) and DIPEA (0.78 mL, 4.4 mmol) were added to a 10 mL solution. The reaction mixture was stirred at room temperature and monitored by TLC. After the reaction was completed, CH 2 Cl 2 The mixture was extracted with 4% paraformaldehyde (2x30 mL), and the combined organic layers were washed with brine (20 mL) and diluted with Na 2 SO 4 The residue was purified by chromatography on silica gel to give the product 24 (0.7 g, 79%) as a colorless oil. HRMS (ESI) was used for C 39 H 73 N 6 O 13 [M+H] + The calculated value is 833.5236 and the measured value is 833.5231.

[0440] Compound 25: Compound 24 (0.52 g, 0.62 mmol) was dissolved in CH 2 Cl 2 (5.0 mL), then TFA (2.0 mL) was added. The mixture was stirred at room temperature for 3 hours. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by chromatography on silica gel to give the product 25 (0.42 g, 93%) as a colorless oil. HRMS (ESI) for C 31 H 57 N 6 O 13 [M+H] + The calculated value is 721.3984 and the measured value is 721.3997.

[0441] Compound 26: Compound 18 (0.58 g, 0.24 mmol), EDCI (82 mg, 0.43 mmol) and HOBt (14 mg, 0.11 mmol) were added to a solution of compound 25 (77 mg, 0.11 mmol) in DMF (2 mL) under argon at room temperature. The reaction mixture was stirred at room temperature and monitored by HPLC. After the reaction was completed, the mixture was concentrated using a rotary evaporator. The crude reaction mixture was purified by HPLC using a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 26 (0.23 g, 38%) as a light yellow solid. HRMS (ESI) was used for C 285 H 463 N 50 O 65 [M+3H] 3+ The calculated value is 1876.4854, and the measured value is 1876.4851. 285 H 464 N 50 O 65 [M+4H] 4+ The calculated value is 1407.6160 and the measured value is 1407.6158.

[0442] Compound 27: Lindlar catalyst (130 mg, 5 wt%) was added to a stirred solution of azide 26 (180 mg, 0.03 mmol) in methanol (10 mL). The reaction flask was evacuated and flushed with hydrogen. The reaction mixture was stirred at room temperature for 5 hours under a hydrogen environment (balloon). After completion of the reaction, the catalyst was filtered through a Celite pad, the filter cake was washed with methanol (10 mL), and the filtrate was concentrated under reduced pressure. The residue was purified using HPLC with a prefabricated Welch Ultimate XB-C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 27 (130 mg, 74%) as a light yellow solid. HRMS (ESI) was used for C 285 H 465 N 48 O 65 [M+3H] 3+ The calculated value is 1867.8219, and the measured value is 1867.8217. 285 H 466 N 48 O 65 [M+4H] 4+ The calculated value is 1401.1184 and the measured value is 1401.1181.

[0443] Example 9: Preparation of Compound 32 (30kmPEG(maleimide)-2MMAE) Fig.10 )

[0444] Compound 29: H-Lys(boc)-OH (369 mg, 1.5 mmol) was added to anhydrous DMF (100 mL), followed by DIPEA (0.83 mL, 5.0 mmol), compound 28 (15 g, 0.5 mmol) and anhydrous CH 2 Cl 2 (150 mL). The mixture was stirred at room temperature overnight under argon. The insoluble material was filtered off. The solvent was removed and the residue was purified by distillation from CH 2 Cl 2 / methyl tert-butyl ether (45mL / 300mL) recrystallization. The isolated solid was recrystallized from MeCN / 2-propanol (30mL / 450mL). The product was vacuum dried at 40°C for 4 hours to give the product 29 (13.6g, 91%) as a white powder. 13C-NMR (126MHz, CDCl3) δ 172.74, 155.65, 155.55, 78.41, 70.13 (PEG), 63.66, 58.55, 52.99, 39.90, 31.70, 29.17, 28.08, 21.97.

[0445] Compound 30: TFA (29.5 mL) was added to a solution of compound 29 (5.7 g, 0.19 mmol) in 57 mL of anhydrous CH 2 Cl 2 (57 mL) solution. The mixture was stirred at room temperature for 1 hour. The solvent was removed as much as possible in vacuo at <35°C. The residue was purified by distillation from CH 2 Cl 2 / methyl tert-butyl ether (14.5 mL / 115 mL) and recrystallized twice. The isolated product was dried in vacuo at 40°C to give the product 30 (4.7 g, 84%) as a white powder.

[0446] Compound 31: DIPEA (473 mg, 3.6 mmol) was added to anhydrous CH 2 Cl 2 (55 mL) was stirred and then NHS-PEG was added 2 -Mal (0.2 g, 0.47 mmol). The mixture was stirred at 0°C for 1.5 hours, and then the solution was slowly heated from 0°C to room temperature and stirred overnight under argon. The solvent was removed and the residue was purified by centrifugation from CH 2 Cl 2 / methyl tert-butyl ether (13.8 mL / 110 mL) recrystallization. The separated solid is recrystallized again from MeCN / 2-propanol (11 mL / 165 mL). The solid is dried under vacuum to give compound 31 (5.0 g, 90%) as a white powder. 13C-NMR (126 MHz, CDCl3) δ 172.76, 171.46, 170.01, 169.94, 155.55, 133.82, 71.37, 70.01 (PEG), 69.05, 68.92, 66.49, 63.53, 58.44, 52.92, 38.65, 36.01, 33.84, 33.71, 31.36, 28.21, 21.85.

[0447] Compound 32: Under argon at room temperature, in DMF / CH 2 Cl 2 Compound 13 (0.12 g, 0.05 mmol), DCC (31 mg, 0.15 mmol) and DMAP (28 mg, 0.23 mmol) were added to a stirred solution of compound 31 (0.76 g, 0.025 mmol) in a (5 mL / 5 mL) mixed solvent. The reaction mixture was stirred at room temperature and monitored by HPLC. After the reaction was complete, the mixture was concentrated using a rotary evaporator. A prefabricated HPLC with Phenomenex The residue was purified by HPLC on a C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 32 (0.36 g, 47%) as a white solid. MS (MALDI-TOF) m / z 33863.

[0448] Example 10: Preparation of Compound 35 (20kmPEG(maleimide)-4MMAE) Fig.11 )

[0449] Compound 33: The synthesis of compound 33 was based on the preparation of compound 31.

[0450] Compound 34: Compound 33 (2.0 g, 0.1 mmol) was added to anhydrous CH 2 Cl 2 Add DBCO-NH (20 mL) to the stirred solution 2 (83 mg, 0.3 mmol), EDCI (115 mg, 0.6 mmol) and HOBt (122 mg, 0.9 mmol). The reaction mixture was stirred at room temperature and monitored by HPLC. The solvent was removed and the residue was purified from CH 2 Cl 2 / methyl tert-butyl ether (5 mL / 40 mL). The isolated solid was recrystallized again from MeCN / 2-propanol (4 mL / 60 mL). The resulting solid was dried under vacuum at 40°C for 4 hours to give the product 34 (1.9 g, 89%) as a white powder. 13C-NMR (214MHz, CDCl3) δ171.12, 171.08, 170.05, 169.75, 155.64, 150.59 (d, J=21.4Hz), 147.54 (d, J=6.6Hz), 133.82, 131.69 (d, J=13.8Hz), 128.70, 128.27 (d, J=11.3Hz), 127.93 (d, J=5.4Hz), 127.79, 127.39 (d, J=8.3Hz), 126.66, 125.04 (d, J=6.0Hz), 122.46 (d, J=4.9Hz), 121.85 (d, J=11.3Hz), 114.21 (d, J=9.8Hz), 107.38 (d, J=33.6Hz), 70.06 (PEG), 66.59, 63.64 (d, J=7.3Hz), 58.50, 54.97 (d, J=13.3Hz), 54.23 (d, J=59.1Hz ), 38.61, 38.40, 36.31, 34.86 (d, J=18.0Hz), 34.05 (d, J=20.8Hz), 33.89, 33.78, 31.76 (d, J=40.2Hz), 28.31 (d, J=9.8Hz), 21.99 (d, J=17.1Hz).

[0451] Compound 35: Compound 34 (147 mg, 0.007 mmol) was dissolved in anhydrous MeOH (3 mL), and then compound 22 (40 mg, 0.007 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated using a rotary evaporator and the mixture was concentrated using a prefabricated PHENOMENEX® 1000. The residue was purified by HPLC on a C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 35 (41 mg, 22%) as a white solid. MS (MALDI-TOF) m / z 25963.

[0452] Example 11: Preparation of Compound 39 (Maleimide-20mPEG-4MMAE) ( Fig.12 )

[0453] Compound 37: At 0 °C, amine-PEG20k-CO 2 H (36) (1.0 g, 0.05 mmol) in anhydrous CH 2 Cl2 DIPEA (83 μL, 0.5 mmol) was added to the stirred solution (10 mL), followed by 6-maleimidocaproic acid N-hydroxysuccinimide ester (46 mg, 0.15 mmol). The mixture was stirred at 0°C for 1.5 hours, then the solution was slowly heated from 0°C to room temperature and stirred overnight under argon. The solvent was removed and the residue was purified by purifying with CH 2 Cl 2 / methyl tert-butyl ether (2.5 mL / 20 mL). The isolated solid was recrystallized again from MeCN / 2-propanol (2 mL / 30 mL). The residue was dried under vacuum to give compound 37 (0.95 g, 95%) as a white powder.

[0454] Compound 38: Compound 37 (0.9 g, 0.045 mmol) was added to anhydrous CH 2 Cl 2 Add DBCO-NH (9 mL) to the stirred solution 2 (37 mg, 0.14 mmol), EDCI (52 mg, 0.27 mmol) and HOBt (55 mg, 0.41 mmol). The reaction mixture was stirred at room temperature and monitored by HPLC. The solvent was removed and the residue was purified from CH 2 Cl 2 / methyl tert-butyl ether (2.5 mL / 20 mL). The isolated solid was recrystallized again from MeCN / 2-propanol (2 mL / 30 mL). The product was dried under vacuum at 40°C for 4 hours to give the product 38 (0.86 g, 89%) as a white powder.

[0455] Compound 39: Compound 38 (166 mg, 0.007 mmol) was dissolved in anhydrous MeOH (3 mL), and then compound 22 (30 mg, 0.006 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours. The solvent was removed using a rotary evaporator and the precipitate was removed using a pre-prepared 1% phenomenex 100 mL column. The residue was purified by HPLC on a C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 39 (37 mg, 27%) as a white solid. HRMS (ESI) or NMR.

[0456] Example 12: Preparation of Compound 41 (DBCO-20kPEG-4MMAE) Fig.13 )

[0457] Compound 40: At 0 °C, amine-PEG20k-CO 2 H (36) (1.0 g, 0.05 mmol) in anhydrous CH 2 Cl2 DIPEA (83 μL, 0.5 mmol) was added to the stirred solution (10 mL), followed by DBCO-NHS (60 mg, 0.15 mmol). The mixture was stirred at 0°C for 1.5 hours, then the solution was slowly heated from 0°C to room temperature and stirred overnight under argon. The solvent was removed and the residue was purified by centrifugation from CH 2 Cl 2 / methyl tert-butyl ether (2.5 mL / 20 mL). The isolated solid was recrystallized again from MeCN / 2-propanol (2 mL / 30 mL). The residue was dried under vacuum to give compound 40 (0.91 g, 91%) as a white powder.

[0458] Compound 41: Under argon, compound 40 (120 mg, 0.006 mmol) was dissolved in CH 2 Cl 2 / DMF (2mL / 2mL) mixed solvent, followed by the addition of compound 27 (50 mg, 0.009 mmol), EDCI (6.9 mg, 0.036 mmol) and HOBt (7.3 mg, 0.054 mmol). The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated using a rotary evaporator and the prefabricated HPLC with Phenomenex The residue was purified by HPLC on a C18 column (eluent: A = 0.1% TFA in water, B = MeCN) to give compound 41 (53 mg, 36%) as a white solid. MS (MALDI-TOF) m / z 25450 Da.

[0459] Example 13: Preparation of SCAHer2IIxSCAHer2IV (Compound 42) Fig.14 )

[0460] SCAHer2II×SCAHer2IV having the amino acid sequence of SEQ ID NO: 1 was prepared and purified as described in Example 2. Specifically, about 1.6 L of supernatant from the culture medium of host cells expressing SCAHer2II×SCAHer2IV was collected after centrifugation and loaded onto a Ni-charged column (2.6 cm×13 cm) (Cat#AA207311, BestChrome, Shanghai, China) pre-equilibrated with 50 mM sodium phosphate, 100 mM NaCl, pH 7.0. The protein was eluted with a buffer of 50 mM sodium phosphate, 250 mM imidazole, 100 mM NaCl, pH 7.0 and fractionated in 15 mL tubes. The 82 mg captured protein obtained was further purified with a CaptoL column (Cat#17-5478-02, GE Healthcare, NJ). A CaptoL column (1.6 cm x 8 cm) was pre-equilibrated with 50 mM sodium phosphate, 100 mM NaCl, pH 7.0, and the protein was eluted with 75 mM acetic acid, pH 3.0 to yield 58.3 mg of protein. Fig.14 SDS-PAGE and SEC-HPLC analysis of purified compound 42 (SCAHer2II x SCAHer2IV) are shown.

[0461] Example 14: Preparation of 30kmPEG-(SCAHer2IIxSCAHer2IV)-2MMAE (Compound 43, JY201) Fig.15 )

[0462] The protein SCAHer2IIxSCAHer2IV42 was treated with a PBS buffer (pH = 7.4) of a reducing agent TCEP-HCl at room temperature for 30 minutes, and then the pH was adjusted to pH 6.8 with a pH = 4.12 stock solution of 500mM sodium phosphate. The treated protein was concentrated to 5mg / mL before conjugation. The conjugation of SCAHer2IIxSCAHer2IV with 5 to 10 molar equivalents of compound 32 (30kmPEG (maleimide) -2MMAE) was carried out at room temperature for 3 hours. The reaction was quenched with 10mM L-cystine at room temperature for 10 minutes. The final product 30kmPEG-(SCAHer2IIxSCAHer2IV)-2MMAE, JY201 was purified in a 20mM phosphate buffer at pH 6.5 using a cation exchange chromatography column (CMFast Flow, Cat#17-0719-01, GE Healthcare, NJ). Fig.15 A schematically illustrates the reaction scheme for preparing compound 43. The obtained compound 43 was confirmed by SDS-PAGE ( Fig.15 B).

[0463] Example 15: Preparation of SCAHer2IIxSCAHer2IV-20kPEG-4MMAE (Compound 44, JY201b) Fig.16 )

[0464] The protein SCAHer2IIxSCAHer2IV42 was treated with a PBS buffer (pH = 7.4) containing the reducing agent TCEP-HCl at room temperature for 30 minutes, and then the pH was adjusted to pH 6.8 with a 500mM sodium phosphate pH = 4.12 stock solution. The treated protein was concentrated to 5 mg / mL before conjugation. The conjugation of SCAHer2IIxSCAHer2IV with 5 to 10 molar equivalents of compound 41 (DBCO-20kPEG-4MMAE) was carried out at room temperature for 3 hours. The reaction was quenched with 10mM L-cystine at room temperature for 10 minutes. The final product was purified by size exclusion chromatography column HiPrep TM 16 / 60, Sephacryl TM S-300HR (Cat# 17-1167-01, GE Healthcare, NJ) was purified in 20 mM phosphate buffer, pH 6.5. Fig.16 A schematically illustrates the reaction scheme for preparing compound 44 (SCAHer2IIxSCAHer2IV-20kPEG-4MMAE, JY201b). The final compound 44 was confirmed by SDS-PAGE ( Fig.16 B).

[0465] Example 16: In vitro cytotoxicity of compound 43 (JY201) and compound 44 (JY201b) Fig.17 , 18)

[0466] To evaluate the effect of PEGylation on the in vitro cytotoxicity of the PEGylated BsADCs JY201 and JY201b, cell viability assays were performed after incubation of cells with compound 43 (JY201) or compound 44 (JY201b) or controls. Specifically, 4x10 4 10 cells per well and the cells were allowed to adhere. After 6 hours, the cells were treated with the indicated doses of JY201 at 37°C for 72 hours, and then 20 μL of MTS was added to each well according to the manufacturer's protocol. The OD 490nm The absorbance at 4 °C was measured and the percentage of cytotoxicity was calculated.

[0467] Fig.17The results showed that the EC50 of JY201 for SKBR-3 and HCC-827 cells were 2.23nM and 75.55nM, respectively. Since HCC827 cells express much lower levels of Her2 than SKBR-3 (Kayatani, H. et al., 2020, BiochemBiophys Res Commun 532, 341-346), these results indicate that JY201 can induce effective cytotoxicity against tumor cells with low Her2 expression levels. In addition, Fig.17 The results in the left figure show that the single-chain antibody Her2IIxHer2IV did not induce detectable toxicity to SKBR-3, so the cytotoxicity of JY201 was caused by the payload MMAE.

[0468] Using the same method described above, the in vitro cytotoxicity of JY201 against JIMT-1 cells was tested and compared with trastuzumab (T-DM1). Surprisingly, Fig.18 The results of A showed that the EC50 of JY201 was very similar to that of T-DM1 (3.29 μg / mL and 3.74 μg / mL, respectively), although the DAR (drug to antibody ratio) of JY201 was only 2 while that of T-DM1 was 4. These results indicate that the PEGylated BsADC JY201 with only 2 payloads is as potent as T-DM1 with 4 payloads in inducing cytotoxicity in tumor cells in vitro.

[0469] Further experiments were performed to test the in vitro cytotoxicity of JY201b (DAR of 4) and compare it with JY201 and T-DM1 ( Fig.18 B, C, D, and E). The results showed that the PEGylated BsADC JY201b with 4 payloads was more effective than JY201 with 2 payloads ( Fig.18 A and D), and was comparable or more effective than T-DM1 on tumor cell lines at the indicated test concentrations. Notably, in the low-end concentration subset of the tested samples, JY201b performed significantly better than T-DM1 in inducing effective cytotoxicity against tumor cells with low expression of the target antigen (Her2 expression levels: SKBR-3>JIMT-1>ZR75-1, see table below). This advantage, coupled with a better toxicity profile, offers great hope for JY201b in treating cancer patients with low Her2 expression, for whom current treatments are ineffective.

[0470] cell Her2 expression SKBR-3 >3+ JIMT-1 2+ ZR75-1 1+

[0471] Example 17: JY201 internalization in target cells ( Fig.19 )

[0472] To investigate the mechanism of the cytotoxic effect shown in Example 16, the internalization of PEGylated BsADC JY201 by SKBR-3 cells was examined by flow cytometry as described by Matsuzaki (Matsuzaki, S. et al., 2018, International Journal of Cancer 142, 1056-1066). After trypsinization, SKBR-3 cells were washed with PBS containing 2% FBS and incubated at 1×10 7 / mL concentration resuspended. The cell suspension was aliquoted into 100μL / tube. SKBR-3 cells were treated with 10μg / mL Flour647-labeled T-DM1 or JY201 at 4°C overnight. After washing twice with pre-cooled PBS, the cells were incubated at 37°C for the indicated time period to allow T-DM1 and JY201 to internalize. The incubated cells were washed with 3×200μL FACS buffer. After the final wash, 100Ml FACS buffer was added to resuspend the cells for flow cytometry analysis. The internalization rate was calculated using the following formula:

[0473] (Total MFI at 4°C - Total MFI at 37°C) / Total MFI at 4°C x 100%.

[0474] Fig.19 The results showed that at all time points tested, the internalization rate of JY201 in SKBR-3 cells was about twice that of T-DM1, although the affinity of JY201 for the target was much weaker than that of T-DM1 (data not shown). This result means that the dynamic internalization and efflux mechanism adopted by traditional Fc-loaded ADCs may not be applicable to the PEGylated ADCs disclosed in the present invention. It is worth noting that the internalization mechanism associated with the binding of the Fc component of traditional ADCs, such as FcγR or mannose receptors on normal tissues or cells, usually leads to off-target toxicity and even dose-limiting toxicity of ADC drugs (Krop IE, et al., J Clin Oncol, 30, 3234-41, 2012; Uppal, H. et al., 2015, Clin Cancer Res 21, 123-133; Gorovits, B. et al., 2013, Cancer Immunol Immunother 62, 217-223).

[0475] Example 18: JY201 did not flow out of target cells after internalization ( Fig. 20 )

[0476] After internalization, the ADC carried by Fc often flows out of the target cells. This may lead to off-target toxicity, reducing effectiveness and drug resistance. This phenomenon has been attributed to FcRn-mediated recycling (Junghans, RP et al., 1996, Proc Natl Acad Sci USA 93, 5512-5516; Ryman, JT et al., 2017, CPT Pharmacometrics Syst Pharmacol 6, 576-588). It is reported that 50% of internalized trastuzumab flows out of the target cells within 5 minutes of internalization, and this number increases to 85% within 30 minutes of internalization (Barok, M., Joensuu et al., 2014, Breast Cancer Res 16, 209-209).

[0477] To examine whether JY201 effluxes from target cells after internalization, HRP (horseradish peroxidase) was conjugated to JY201 following the manufacturer's protocol. 3x10 4 SK-BR3 cells were cultured overnight to allow the cells to adhere. The next day, the cells were washed and incubated with 0.25μg / mL of JY201 for 18 hours at room temperature. After washing three times with complete medium, the cells were further incubated at 37°C. Cell lysates and supernatants were collected at different time points. The content of JY201-HRP in cell lysates and cell supernatants was detected by adding 50μL / well TMB (3,3′,5,5′-tetramethylbenzidine) solution. After terminating the reaction with 50μL / well 0.2M sulfuric acid, OD450 was measured on a microplate analyzer. The same experiment was performed on T-DM1, and 0.25μg / mL T-DM1-HRP was incubated with cells for 4 hours, then washed, the medium was replaced and further incubated for 2 hours and 24 hours.

[0478] Fig. 20 A shows that the JY201 in the supernatant did not increase significantly after further incubation for 3 hours and 6 hours compared with 0 hours. At the same time, the JY201 in the cell lysate did not decrease at 3 hours and 6 hours ( Fig. 20 B). In addition, the OD450 of the cell lysate was at least 2-fold higher than the OD450 of the supernatant at 0 hours. It can be seen that JY201 was internalized and the internalized JY201 did not flow out into the supernatant.

[0479] For comparison, the level of T-DM1 in the supernatant was also measured, which increased significantly after 2 h of incubation (p<0.001) ( Fig. 20C). In addition, the level of T-DM1 was significantly higher after 24 hours of culture than after 2 hours of culture, indicating the continued efflux of T-DM1. Consistently, T-DM1 in cell lysates was significantly reduced at 24 hours (p<0.001) ( Fig. 20 D) The efflux mechanism of T-DM1 may lead to reduced clinical efficacy and increased toxicity of the drug.

[0480] In general, from Fig. 20 The data suggest the unexpected result that JY201 has no recycling or efflux mechanism, which may be due to the lack of an Fc component in JY201.

[0481] Example 19: JY201 has no cytotoxicity to megakaryocytes ( Fig.21 )

[0482] Thrombocytopenia, characterized by low platelet counts, is a major adverse event in cancer patients treated with ADCs (Uppal, H. et al., 2015, Clin Cancer Res 21, 123-133; Donaghy, H. 2016, MAbs 8, 659-671; de Goeij, BE et al., 2016, Curr Opin Immunol 40, 14-23), which leads to dose-limiting toxicity of T-DM1 (Krop IE, et al., J Clin Oncol, 30, 3234-41, 2012). To examine the cytotoxicity associated with thrombocytopenia of JY201, JY102 was tested for binding and cytotoxicity to DAMI (a megakaryocyte cell line that is the blast of terminally differentiated platelets (Lev, PR et al., 2011, Platelets 22, 28-38)).

[0483] For binding experiments, DAMI cells were harvested and resuspended in ice-cold PBS containing 2% FBS to approximately 5 × 10 6 The cells were then incubated with JY201 or controls and analyzed by flow cytometry using the same method described in Example 17. The in vitro cytotoxicity to DAMI cells was assessed using the same method described in Example 16.

[0484] Fig.21 The results shown in C indicate that the PEGylated BsADC JY201 surprisingly did not induce cytotoxicity against DAMI cells even at a high concentration of 50 μg / mL, whereas T-DM1 induced significant drug-specific cytotoxicity at the tested concentrations. This unexpected result is consistent with Fig.21The results in A and 21B are consistent, in which FITC-labeled T-DM1 binds to DAMI cells, while JY201 does not, probably because it lacks the Fc region.

[0485] In summary, the current data indicate that the cytotoxicity of JY201 is tissue-specific, exerting cytotoxicity only on tumor cells and not on megakaryocytes. The unexpected superior properties of JY201 provide a good opportunity to address some of the major adverse events in the clinic caused by ADC-induced thrombocytopenia and other conditions.

[0486] The foregoing examples and descriptions of preferred embodiments should be considered as illustrative, rather than limiting, of the invention as defined by the claims. It should be readily understood that a variety of variations and combinations of the above features may be utilized without departing from the invention as set forth in the claims. Such variations should not be considered as departing from the scope of the invention, and all such variations are intended to be included within the scope of the appended claims. Sequence Listing <110> Shenzhen Kangyuan Jiuyuan Biotechnology Co., Ltd. <120> Antibody Drug Conjugates <130> F21W8688 <150> PCT / CN2020 / 084880 <151> 2020-04-15 <160> 4 <170> PatentIn Version 3.5 <210> 1 <211> 506 <212> PRT <213> Artificial sequence <220> <223> SCAHer2IIxSCAHer2IV <400> 1 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Gly Gly Ser 100 105 110 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Glu Val Gln Leu Val 115 120 125 Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 130 135 140 Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr Thr Met Asp Trp Val 145 150 155 160 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asp Val Asn Pro 165 170 175 Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe Lys Gly Arg Phe Thr 180 185 190 Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser 195 200 205 Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Leu Gly 210 215 220 Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 225 230 235 240 Ser Ser Gly Cys Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly 245 250 255 Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 260 265 270 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp 275 280 285 Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 290 295 300 Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser 305 310 315 320 Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala 325 330 335 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 340 345 350 Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly 355 360 365 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly 370 375 380 Gly Ser Gly Gly Ser Gly Gly Asp Ile Gln Met Thr Gln Ser Pro Ser 385 390 395 400 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala 405 410 415 Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly 420 425 430 Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly 435 440 445 Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu 450 455 460 Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 465 470 475 480 Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu 485 490 495 Ile Lys Arg Thr His His His His His His 500 505 <210> 2 <211> 507 <212> PRT <213> Artificial sequence <220> <223> SCAHer2IV / SCAHer2IV <400> 2 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Gly Gly Ser 100 105 110 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Glu Val Gln Leu Val 115 120 125 Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 130 135 140 Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val 145 150 155 160 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro 165 170 175 Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 180 185 190 Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser 195 200 205 Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly 210 215 220 Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 225 230 235 240 Val Ser Ser Gly Cys Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser 245 250 255 Gly Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser 260 265 270 Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn 275 280 285 Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu 290 295 300 Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe 305 310 315 320 Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu 325 330 335 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr 340 345 350 Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Gly 355 360 365 Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Glu Val Gln 370 375 380 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 385 390 395 400 Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His 405 410 415 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 420 425 430 Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg 435 440 445 Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met 450 455 460 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp 465 470 475 480 Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 485 490 495 Val Thr Val Ser Ser His His His His His His 500 505 <210> 3 <211> 508 <212> PRT <213> Artificial sequence <220> <223> SCAHer2IVxSCAHer3 <400> 3 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Gly Gly Ser 100 105 110 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Glu Val Gln Leu Val 115 120 125 Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 130 135 140 Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val 145 150 155 160 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro 165 170 175 Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 180 185 190 Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser 195 200 205 Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly 210 215 220 Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 225 230 235 240 Val Ser Ser Gly Cys Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser 245 250 255 Gly Gly Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro 260 265 270 Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser 275 280 285 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 290 295 300 Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Thr Asn Pro Ser 305 310 315 320 Leu Lys Ser Arg Val Thr Ile Ser Val Glu Thr Ser Lys Asn Gln Phe 325 330 335 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 340 345 350 Cys Ala Arg Asp Lys Trp Thr Trp Tyr Phe Asp Leu Trp Gly Arg Gly 355 360 365 Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser 370 375 380 Gly Gly Ser Gly Gly Asp Ile Glu Met Thr Gln Ser Pro Asp Ser Leu 385 390 395 400 Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln 405 410 415 Ser Val Leu Tyr Ser Ser Ser Asn Arg Asn Tyr Leu Ala Trp Tyr Gln 420 425 430 Gln Asn Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr 435 440 445 Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 450 455 460 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val 465 470 475 480 Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly 485 490 495 Thr Lys Val Glu Ile Lys His His His His His His 500 505 <210> 4 <211> 501 <212> PRT <213> Artificial Sequence <220> <223> SCAc-Met1xSCAc-Met2 <400> 4 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Val Ser Ser Ser Val Ser Ser Ile 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ile Gln Tyr Ser Gly Tyr Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly 100 105 110 Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gln Val Gln Leu Val Gln 115 120 125 Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys 130 135 140 Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met His Trp Val Arg 145 150 155 160 Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Val Asn Pro Asn 165 170 175 Arg Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu Gly Arg Val Thr Met 180 185 190 Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu 195 200 205 Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Asn Trp Leu 210 215 220 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Gly Cys Gly Ser 225 230 235 240 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gln Val Gln Leu Val 245 250 255 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ala Tyr Thr Met His Trp Val 275 280 285 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Lys Pro 290 295 300 Asn Asn Gly Leu Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr 305 310 315 320 Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg 325 330 335 Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Glu Ile 340 345 350 Thr Thr Glu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 355 360 365 Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Asp 370 375 380 Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu 385 390 395 400 Arg Ala Thr Ile Asn Cys Lys Ser Ser Glu Ser Val Asp Ser Tyr Ala 405 410 415 Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys 420 425 430 Leu Leu Ile Tyr Arg Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg 435 440 445 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 450 455 460 Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Lys Glu 465 470 475 480 Asp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg His 485 490 495 His His His His His 500

Claims

1. Compounds of formula (Ib) in: P is a non-immunogenic polymer, wherein the non-immunogenic polymer is polyethylene glycol (PEG) and the total molecular weight of the PEG is 10,000 to 80,000; M is H or selected from C 1-25 Alkyl and aryl end-capping groups, wherein one or more carbons of the alkyl group are optionally substituted with heteroatoms; Y is 1; A is an antibody fragment, and T is a trifunctional linker derived from a molecule having three functional groups independently selected from hydroxyl, amino, hydrazine, azide, olefin, alkyne, aldehyde, ketone, ester, carboxylic acid, anhydride, acyl halide, thiol, disulfide, nitrile, epoxide, imine, nitro and halide, and wherein T and (L 1 ) a The connection between T and (L 2 ) b The connections between them are the same or different; L 1 and L 2 Each independently selected from: -(CH2) p XY(CH2) q -, -X(CH2) p O(CH2CH2O) c (CH2) q Y-, -(CH2) p Heterocyclyl-, -(CH2) p X-, -X(CH2) p AND-, -W1-(CH2) p C(O)NR1(CH2) q O(CH2CH2O) c (CH2) d C(O)-, -C(O)(CH2) p O(CH2CH2O) q (CH2) c W2C(O)(CH2) d NR1-, -W3-(CH2) p C(O)NR1(CH2) q O(CH2CH2O) c (CH2) d W2C(O)(CH2) e C(O)-, wherein p, q, c, d and e are each independently an integer selected from 0 to 25; X and Y are each independently selected from C(=O), NR1, S, O, CR2R3 or none; R1 and R2 independently represent hydrogen, C 1-10 Alkyl or (CH2) 1-10 C(=O); W1 and / or W3 are derived from a maleimido-based moiety, and W2 represents a triazolyl- or tetrazolyl-containing group; the heterocyclic group is selected from a maleimido-derived moiety or a tetrazolyl- or triazolyl-based moiety; a and b are each an integer selected from 0 to 10; B is a branched connector; The branched linker B comprises an extended spacer, a trigger unit and a self-destructive spacer, wherein the trigger unit is an amino acid sequence or a β-glucuronide or β-galactoside trigger portion that can be cleaved by an enzyme; D are each independently a cytotoxic small molecule or a peptide; and n is an integer selected from 1-25.

2. The compound of claim 1, wherein T is lysine or is derived from lysine.

3. The compound of claim 1 or 2, wherein said L 1 The functional group at the end of the linker is capable of site-specific conjugation with A and is selected from thiol, maleimide, 2-pyridyl dithio variant, aromatic sulfone or vinyl sulfone, acrylate, bromo or iodoacetamide, azide, alkyne, dibenzocyclooctyl (DBCO), carbonyl, 2-amino-benzaldehyde or 2-amino-acetophenone group, hydrazide, oxime, potassium acyl trifluoroborate, O-carbamoylhydroxylamine, trans-cyclooctene, tetrazine, triarylphosphine, boronic acid and iodine.

4. The compound of any one of claims 1 to 3, wherein the antibody fragment is a monospecific or multispecific single chain antibody, a nanobody or an antigen binding domain thereof.

5. The compound of any one of claims 1 to 4, wherein the antibody fragment is a monospecific single chain antibody.

6. The compound of claim 5, wherein the monospecific single chain antibody binds to a tumor associated antigen (TAA).

7. The compound of claim 6, wherein the monospecific single chain antibody binds to Her2.

8. The compound of claim 6 or 7, wherein the monospecific single chain antibody has two binding domains that bind to Her2.

9. The compound of claim 8, wherein the monospecific single-chain antibody has the amino acid sequence shown in SEQ ID NO:

2.

10. The compound of any one of claims 1 to 4, wherein the antibody fragment is a bispecific antibody.

11. The compound of claim 10, wherein the antibody fragment is a bispecific single chain antibody.

12. The compound of claim 10 or 11, wherein the two binding domains of the bispecific antibody bind to the same tumor-associated antigen (TAA), to two different TAAs, or to a TAA and an antigen expressed on T cells or NK cells.

13. The compound of claim 12, wherein the T cell is a component of a T cell receptor.

14. The compound of claim 12, wherein the antibody fragment is an anti-Her2 x anti-Her2 single chain bispecific antibody.

15. The compound of claim 14, wherein the antibody fragment has the amino acid sequence shown in SEQ ID NO:

1.

16. The compound of any one of claims 5 to 9, wherein the two binding domains of the monospecific single-chain antibody are connected by a linker, and wherein the linker comprises cysteine ​​or a non-natural amino acid residue for binding of the antibody fragment to L 1 Site-specific conjugation.

17. The compound of any one of claims 10 to 15, wherein the two binding domains of the bispecific single chain antibody are connected by a linker, and wherein the linker comprises cysteine ​​or a non-natural amino acid residue for binding of the antibody fragment to L 1 Site-specific conjugation.

18. The compound of claim 16 or 17, wherein the unnatural amino acid is selected from the group consisting of the genetically encoded alkene lysine, 2-amino-8-oxononanoic acid, m- or p-acetylphenylalanine, an amino acid containing a β-diketone side chain, (S)-2-amino-6-(((1R,2R)-2-azidocyclopentyloxy)carbonylamino)hexanoic acid, azidohomoalanine, the pyrrolysine analog N6-((prop-2-yn-1-oxy)carbonyl)-L-lysine, (S)-2-amino-6-pentan-4-aminohexanoic acid, (S) -2-amino-6-((prop-2-ynyloxy)carbonylamino)hexanoic acid, (S)-2-amino-6-((2-azidoethoxy)carbonylamino)hexanoic acid, p-azidophenylalanine, p-azidophenylalanine, Nε-acryloyl-1-lysine, Nε-5-norbornene-2-oxycarbonyl-1-lysine, N-ε-(cyclooct-2-yn-1-oxy)carbonyl)-L-lysine, N-ε-(2-(cyclooct-2-yn-1-oxy)ethyl)carbonyl-L-lysine, genetically encoded tetrazine amino acids.

19. The compound of claim 18, wherein the genetically encoded alkene lysine is N6-(hex-5-enoyl)-L-lysine.

20. The compound of claim 18, wherein the amino acid containing a [beta]-diketone side chain is 2-amino-3-(4-(3-oxobutanoyl)phenyl)propanoic acid.

21. The compound of claim 18, wherein the tetrazine amino acid encoded by the gene is 4-(6-methyl-s-tetrazin-3-yl)aminophenylalanine.

22. The compound of any one of claims 1 to 21, wherein D is selected from a DNA cross-linking agent, a microtubule inhibitor, a DNA alkylating agent, a topoisomerase inhibitor, or a combination thereof.

23. The compound of claim 22, wherein D is selected from MMAE, MMAF, SN38, DM1, DM4, echinococcal toxins, pyrrolobenzodiazepines, duocarmycins or derivatives thereof, or combinations thereof.

24. The compound of claim 22, wherein D is selected from the group consisting of a vinca alkaloid, laulimalide, a taxane, colchicine, tubulysin, Cryptophycin, Hemiasterlin, Cemadotin, Rhizoxin, Discodermolide, taccalonolide A or B or AF or AJ, taccalonolide AI-epoxide, CA-4, epothilones A and B, paclitaxel, docetaxel, doxorubicin, camptothecin, iSGD-1882, centanamycin, PNU-159682, uncialamycin, an indolebenzodiazepine dimer, β-amanitin, amatoxin, thailanstatin, or a derivative or analog thereof, or a combination thereof.

25. The compound of any one of claims 1-24, wherein the PEG is a linear PEG or a branched PEG.

26. The compound of any one of claims 1 to 25, wherein at least one terminal of the polyethylene glycol is capped with a methyl group or a low molecular weight alkyl group.

27. The compound of any one of claims 1 to 26, wherein the total molecular weight of the PEG is 20,000-40,000.

28. The compound of any one of claims 1 to 27, wherein the PEG is linked to a trifunctional or tetrafunctional or any other cyclic or acyclic multifunctional moiety T via a permanent or cleavable bond.

29. The compound of claim 28, wherein said T is lysine.

30. The compound of any one of claims 1 to 29, wherein (L 1 ) a and (L 2 ) b Each independently selected from: wherein n and m are integers and are independently selected from 0 to 20.

31. The compound of any one of claims 1 to 30, wherein the enzyme is selected from cathepsin B, plasmin, matrix metalloproteinases, β-glucuronidase and β-galactosidase.

32. The compound of claim 31, wherein the branched linker B is selected from in: a, b, c, d, e and f are each an integer and are independently selected from 1 to 25; (A) n It is the amino acid sequence trigger unit; PAB is p-aminobenzyl alcohol; Ex are each extended spacers comprising a linker chain, independently selected from: -NR 1 (CH2) x O(CH2CH2O) y (CH2) z C(O)-, -C(O)(CH2) x NR 1 -, NR 1 (CH2) x O(CH2CH2O) y (CH2) z No. 2 -, -NR 1 (CH2) x NR 2 -, NR 1 (CH2) x O(CH2CH2O) y (CH2) z A-, -O(CH2) x No. 1 -, -C(O)(CH2) x O-, -O(CH2) x O(CH2CH2O) y (CH2) z C(O)-, -C(O)(CH2) x O(CH2CH2O) y (CH2) z C(O)-, -C(O)(CH2) x C(O)-, or none, wherein x, y and z are each an integer independently selected from 0 to 25; R 1 and R 2 independently represents hydrogen or C 1-10 alkyl.

33. The compound of claim 32, wherein the amino acid sequence trigger unit is selected from Val-Cit, al-Ala, Val-Lys, Phe-Lys, Phe-Cit, Phe-Arg, Phe-Ala, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, D-Phe-LPhe-Lys, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Gly-Phe-Leu-Gly or Ala-Leu-Ala-Leu.

34. A compound according to any one of claims 1 to 30, wherein the branched linker B is selected from 35. The compound of claim 1 selected from the following formula: or a pharmaceutically acceptable salt thereof.

36. A method for preparing a compound according to any one of claims 1 to 35, comprising: a) a step of preparing a non-immunogenically modified drug conjugate having a free functional group for site-specific conjugation; b) a step of site-specifically conjugating the non-immunogenic modified drug conjugate to an antibody fragment to provide a compound of formula (Ib).

37. The method of claim 36, wherein the non-immunogenically modified drug conjugate is a pegylated drug conjugate.

38. A pharmaceutical formulation comprising an effective amount of a compound according to any one of claims 1 to 35 and a pharmaceutically acceptable salt, carrier or excipient.

39. Use of a compound according to any one of claims 1 to 35 in the preparation of a medicament for treating cancer selected from breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, salivary gland cancer, thyroid cancer and endometrial cancer.

40. Use of a compound according to any one of claims 1 to 35 in combination with an effective amount of another anticancer agent, an immunosuppressant in the preparation of a medicament for treating cancer, wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, salivary gland cancer, thyroid cancer and endometrial cancer.

41. The use of claim 39 or 40, wherein The colorectal cancer is colon cancer.

Citation Information

Patent Citations

  • Cytotoxic agents comprising maytansinoids and their therapeutic use

    EP0425235A2

  • Polylactide-drug mixtures

    US3773919A

  • Method and means for the early detection and diagnosis of certain types of cancers

    US4150149A

  • Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

    US4361544A

  • Osmotic drug delivery system

    US4439196A